{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:09:36Z","timestamp":1790248176589,"version":"4.1.0"},"reference-count":686,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002920","name":"Research Grants Council, University Grants Committee","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pharmr.2026.100150","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:27:40Z","timestamp":1782491260000},"page":"100150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases"],"prefix":"10.1016","volume":"78","author":[{"given":"Zara Siu Wa","family":"Chui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-6973","authenticated-orcid":false,"given":"Xiaoping","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","article-title":"The global burden of metabolic disease: Data from 2000 to 2019","volume":"35","author":"Chew","year":"2023","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155999","article-title":"Global burden of metabolic diseases, 1990-2021","volume":"160","author":"Zhang","year":"2024","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2017-000505","article-title":"Multimorbidity and out-of-pocket expenditure on medicines: a systematic review","volume":"3","author":"Sum","year":"2018","journal-title":"BMJ Glob Health"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib6","doi-asserted-by":"crossref","DOI":"10.7861\/clinmed.2021-0370","article-title":"Managing obesity in people with type 2 diabetes","volume":"21","author":"Grant","year":"2021","journal-title":"Clin Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in obese older patients with heart failure with preserved ejection fraction: a randomized clinical Trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1614362","article-title":"Health effects of overweight and obesity in 195 countries over 25 years","volume":"377","author":"Afshin","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib10","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","article-title":"Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms","volume":"116","author":"Hall","year":"2015","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction-associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib13","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1056\/NEJMsr1606602","article-title":"Body fatness and cancer--viewpoint of the IARC working group","volume":"375","author":"Lauby-Secretan","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100150_bib14","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s13679-020-00422-w","article-title":"Long-term efficacy and safety of anti-obesity treatment: where do we stand?","volume":"10","author":"Tak","year":"2021","journal-title":"Curr Obes Rep"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib16","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1056\/NEJMp2003873","article-title":"Cancer risk associated with lorcaserin - The FDA's review of the CAMELLIA-TIMI 61 trial","volume":"383","author":"Sharretts","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmr.2026.100150_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"10355","key":"10.1016\/j.pharmr.2026.100150_bib18","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","author":"Cholesterol Treatment Trialists","year":"2022","journal-title":"Lancet"},{"issue":"34","key":"10.1016\/j.pharmr.2026.100150_bib19","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/eurheartj\/ehac015","article-title":"Prevalence of statin intolerance: a meta-analysis","volume":"43","author":"Byty\u00e7i","year":"2022","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S2213-8587(24)00217-1","article-title":"Risk of new-onset diabetes with high-intensity statin use","volume":"12","author":"Diamond","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib22","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2468-1253(24)00049-9","article-title":"Resmetirom for NASH: balancing promise and prudence","volume":"9","author":"The Lancet Gastroenterology","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100150_bib25","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"issue":"9716","key":"10.1016\/j.pharmr.2026.100150_bib26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00125-015-3528-5","article-title":"Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort","volume":"58","author":"Cederberg","year":"2015","journal-title":"Diabetologia"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100150_bib28","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"357","author":"Holman","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib29","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.2337\/diacare.26.6.1902","article-title":"Hypoglycemia in diabetes","volume":"26","author":"Cryer","year":"2003","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.pcad.2017.09.001","article-title":"Insulin therapy increases cardiovascular risk in type 2 diabetes","volume":"60","author":"Herman","year":"2017","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib31","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41573-020-00135-8","article-title":"Trends in peptide drug discovery","volume":"20","author":"Muttenthaler","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.tem.2006.10.011","article-title":"Mechanisms of peptide hormone secretion","volume":"17","author":"Michael","year":"2006","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib34","first-page":"141","article-title":"Pancreatic extracts in the treatment of diabetes mellitus","volume":"12","author":"Banting","year":"1922","journal-title":"Can Med Assoc J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0021-9258(18)85474-6","article-title":"Aqueous extracts of pancreas: III. Some precipitation reactions of insulin","volume":"58","author":"Kimball","year":"1923","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0031-6997(25)06715-8","article-title":"Human growth hormone","volume":"46","author":"Strobl","year":"1994","journal-title":"Pharmacol Rev"},{"issue":"1977","key":"10.1016\/j.pharmr.2026.100150_bib37","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1126\/science.198.4317.594","article-title":"The 1977 Nobel Prize in physiology or medicine","volume":"198","author":"Meites","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.pharmr.2026.100150_bib38","first-page":"620","article-title":"Sur les possibilities d'un traitement du diabete par. L'incretine","volume":"12","author":"BARRE","year":"1932","journal-title":"Bull Acad R Med Belg"},{"issue":"6505","key":"10.1016\/j.pharmr.2026.100150_bib39","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3803\/EnM.2016.31.1.1","article-title":"The Impact of Organokines on Insulin Resistance, Inflammation, and Atherosclerosis","volume":"31","author":"Choi","year":"2016","journal-title":"Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib41","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.tips.2015.04.014","article-title":"Adipokines in health and disease","volume":"36","author":"Fasshauer","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib42","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib43","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1210\/endrev\/bnaa016","article-title":"Muscle-organ crosstalk: the emerging roles of myokines","volume":"41","author":"Severinsen","year":"2020","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.molmed.2010.12.003","article-title":"The cardiokine story unfolds: ischemic stress-induced protein secretion in the heart","volume":"17","author":"Doroudgar","year":"2011","journal-title":"Trends Mol Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib45","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41574-022-00641-2","article-title":"Exerkines in health, resilience and disease","volume":"18","author":"Chow","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.pharmr.2026.100150_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/bs.acc.2019.07.012","article-title":"Organokines in disease","volume":"94","author":"Chung","year":"2020","journal-title":"Adv Clin Chem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib47","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00125-023-05956-x","article-title":"Incretin hormones and type 2 diabetes","volume":"66","author":"Nauck","year":"2023","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib48","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40265-023-01992-4","article-title":"Tirzepatide: a review in type 2 diabetes","volume":"84","author":"France","year":"2024","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100150_bib49","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib50","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","article-title":"Targeting the incretin system in obesity and type 2 diabetes mellitus","volume":"20","author":"Ansari","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib51","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41574-025-01125-9","article-title":"Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus","volume":"21","author":"Walker","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib52","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42255-023-00812-z","article-title":"Gut hormone co-agonists for the treatment of obesity: from bench to bedside","volume":"5","author":"Nogueiras","year":"2023","journal-title":"Nat Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib53","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41574-018-0118-x","article-title":"Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases","volume":"15","author":"Clemmensen","year":"2019","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib54","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as Compared with Semaglutide for the Treatment of Obesity","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib55","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs Tirzepatide for weight loss in adults with overweight or obesity","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib56","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib57","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/dom.15410","article-title":"Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: a systematic review and multilevel meta-analysis","volume":"26","author":"Karakasis","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"10456","key":"10.1016\/j.pharmr.2026.100150_bib58","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib60","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","article-title":"Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study","volume":"82","author":"Xiang","year":"2025","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib61","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib62","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib63","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib64","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S2468-1253(23)00272-8","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib65","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41574-020-0386-0","article-title":"The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic","volume":"16","author":"Geng","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100150_bib66","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1073\/pnas.76.1.106","article-title":"Expression in Escherichia coli of chemically synthesized genes for human insulin","volume":"76","author":"Goeddel","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib68","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/s41565-023-01565-2","article-title":"Oral nanotherapeutic formulation of insulin with reduced episodes of hypoglycaemia","volume":"19","author":"Hunt","year":"2024","journal-title":"Nat Nanotechnol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib69","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/dom.14901","article-title":"Oral insulin (ORMD-0801) in type 2 diabetes mellitus: a dose-finding 12-week randomized placebo-controlled study","volume":"25","author":"Eldor","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib70","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.2337\/dc24-0838","article-title":"A randomized comparison of postprandial glucose excursion using inhaled insulin versus rapid-acting analog insulin in adults with type 1 diabetes using multiple daily injections of insulin or automated insulin delivery","volume":"47","author":"Hirsch","year":"2024","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib71","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40262-021-01084-0","article-title":"Comparison of pharmacokinetics and pharmacodynamics of inhaled technosphere insulin and subcutaneous insulin lispro in the treatment of type 1 diabetes mellitus","volume":"61","author":"Grant","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib72","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.2337\/diab.42.12.1700","article-title":"Intensive insulin therapy and weight gain in IDDM","volume":"42","author":"Carlson","year":"1993","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib73","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib74","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1038\/s41467-021-24816-z","article-title":"Insulin signaling regulates longevity through protein phosphorylation in Caenorhabditis elegans","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"issue":"6454","key":"10.1016\/j.pharmr.2026.100150_bib75","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/366461a0","article-title":"elegans mutant that lives twice as long as wild type","volume":"366","author":"Kenyon","year":"1993","journal-title":"Nature"},{"issue":"5606","key":"10.1016\/j.pharmr.2026.100150_bib76","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1126\/science.1078223","article-title":"Extended longevity in mice lacking the insulin receptor in adipose tissue","volume":"299","author":"Bluher","year":"2003","journal-title":"Science"},{"issue":"7349","key":"10.1016\/j.pharmr.2026.100150_bib77","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0140-6736(64)90011-X","article-title":"New interpretation of oral glucose tolerance","volume":"2","author":"McIntyre","year":"1964","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib78","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Plasma insulin response to oral and intravenous glucose administration","volume":"24","author":"Elrick","year":"1964","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib79","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1113\/jphysiol.1970.sp009155","article-title":"Further purification of a polypeptide demonstrating enterogastrone activity","volume":"209","author":"Brown","year":"1970","journal-title":"J Physiol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib80","first-page":"912","article-title":"Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations","volume":"76","author":"Nauck","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib81","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/BF00257346","article-title":"Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption","volume":"24","author":"Ebert","year":"1983","journal-title":"Diabetologia"},{"issue":"5924","key":"10.1016\/j.pharmr.2026.100150_bib82","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100150_bib83","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1073\/pnas.80.18.5485","article-title":"Mammalian pancreatic preproglucagon contains three glucagon-related peptides","volume":"80","author":"Lopez","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib84","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1210\/jc.2002-021479","article-title":"Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans","volume":"88","author":"Vahl","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib85","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol Rev"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib86","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1002\/oby.20154","article-title":"High protein intake stimulates postprandial GLP1 and PYY release","volume":"21","author":"van der Klaauw","year":"2013","journal-title":"Obesity"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib87","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.metabol.2009.07.039","article-title":"Effects of meal size and composition on incretin, \u03b1-cell, and \u03b2-cell responses","volume":"59","author":"Rijkelijkhuizen","year":"2010","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib88","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib89","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"issue":"6427","key":"10.1016\/j.pharmr.2026.100150_bib90","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/363356a0","article-title":"Calcium-independent potentiation of insulin release by cyclic AMP in single \u03b2-cells","volume":"363","author":"Ammala","year":"1993","journal-title":"Nature"},{"issue":"49","key":"10.1016\/j.pharmr.2026.100150_bib91","doi-asserted-by":"crossref","first-page":"19333","DOI":"10.1073\/pnas.0707054104","article-title":"Essential role of Epac2\/Rap1 signaling in regulation of insulin granule dynamics by cAMP","volume":"104","author":"Shibasaki","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib92","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.molmet.2014.08.001","article-title":"CREB mediates the insulinotropic and anti-apoptotic effects of GLP-1 signaling in adult mouse \u03b2-cells","volume":"3","author":"Shin","year":"2014","journal-title":"Mol Metab"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib93","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.metabol.2014.05.008","article-title":"Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells","volume":"63","author":"Li","year":"2014","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib94","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0167-4838(00)00270-3","article-title":"Different domains in the third intracellular loop of the GLP-1 receptor are responsible for G\u03b1s and G\u03b1i\/G\u03b1o activation","volume":"1546","author":"Hallbrink","year":"2001","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib95","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1038\/s41467-023-41893-4","article-title":"GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics","volume":"14","author":"Wright","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib96","article-title":"Expression profile of the GLP-1 receptor in the gastrointestinal tract and pancreas in adult female mice","volume":"163","author":"Grunddal","year":"2022","journal-title":"Endocrinology"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100150_bib97","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13852","article-title":"GLP-1 suppresses glucagon secretion in human pancreatic alpha-cells by inhibition of P\/Q-type Ca(2+) channels","volume":"6","author":"Ramracheya","year":"2018","journal-title":"Physiol Rep"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib98","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cmet.2016.08.020","article-title":"Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes","volume":"24","author":"Segerstolpe","year":"2016","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib99","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.molmet.2016.04.007","article-title":"Comprehensive alpha, beta and delta cell transcriptomes reveal that ghrelin selectively activates delta cells and promotes somatostatin release from pancreatic islets","volume":"5","author":"DiGruccio","year":"2016","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib100","doi-asserted-by":"crossref","first-page":"341","DOI":"10.32598\/bcn.2021.2554.2","article-title":"Investigating the glucagon-like peptide-1 and its receptor in human brain: distribution of expression, functional implications, age-related changes and species specific characteristics","volume":"14","author":"Gupta","year":"2023","journal-title":"Basic Clin Neurosci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib101","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1210\/en.2017-00812","article-title":"Characterization of the glucagonlike peptide-1 receptor in male mouse brain using a novel antibody and in situ hybridization","volume":"159","author":"Jensen","year":"2018","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib102","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s42255-021-00344-4","article-title":"Central and peripheral GLP-1 systems independently suppress eating","volume":"3","author":"Brierley","year":"2021","journal-title":"Nat Metab"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib103","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib104","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/db23-0972","article-title":"GLP-1 receptor agonist treatment improves fasting and postprandial lipidomic profiles independently of diabetes and weight loss","volume":"73","author":"Della Pepa","year":"2024","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib105","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41366-019-0513-y","article-title":"Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob\/ob mice","volume":"44","author":"Xu","year":"2020","journal-title":"Int J Obes"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib106","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.molmet.2014.09.005","article-title":"GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance","volume":"3","author":"Taher","year":"2014","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib107","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.3390\/ijms25052961","article-title":"Semaglutide improves liver steatosis and de novo lipogenesis markers in obese and type-2-diabetic mice with metabolic-dysfunction-associated steatotic liver disease","volume":"25","author":"Soto-Catalan","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib108","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib109","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib110","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","article-title":"Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation","volume":"42","author":"McLean","year":"2021","journal-title":"Endocr Rev"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100150_bib111","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153732","article-title":"Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide","volume":"6","author":"McLean","year":"2021","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib112","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1210\/en.2018-00004","article-title":"GLP-1 Receptor Expression Within the Human Heart","volume":"159","author":"Baggio","year":"2018","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2026.100150_bib113","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.peptides.2017.02.008","article-title":"Exendin-4 inhibits structural remodeling and improves Ca(2+) homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS\/cGMP\/PKG pathway","volume":"90","author":"Chen","year":"2017","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib114","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2337\/diabetes.54.1.146","article-title":"Glucagon-like peptide 1 can directly protect the heart against ischemia\/reperfusion injury","volume":"54","author":"Bose","year":"2005","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib115","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"Mentlein","year":"1993","journal-title":"Eur J Biochem"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib116","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1210\/endo.140.11.7143","article-title":"Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine","volume":"140","author":"Hansen","year":"1999","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib117","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib118","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2002-29087","article-title":"Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4","volume":"110","author":"Thum","year":"2002","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib119","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","article-title":"Exenatide: pharmacokinetics, clinical use, and future directions","volume":"18","author":"Knop","year":"2017","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib120","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0922-4106(94)90085-X","article-title":"Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2","volume":"269","author":"Schepp","year":"1994","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100150_bib121","doi-asserted-by":"crossref","first-page":"3905","DOI":"10.1111\/bph.15134","article-title":"Signalling, trafficking and glucoregulatory properties of glucagon-like peptide-1 receptor agonists exendin-4 and lixisenatide","volume":"177","author":"Pickford","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib122","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1021\/jm9909645","article-title":"Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration","volume":"43","author":"Knudsen","year":"2000","journal-title":"J Med Chem"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100150_bib123","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"issue":"2-3","key":"10.1016\/j.pharmr.2026.100150_bib125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1515\/jbcpp-2025-0026","article-title":"The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers","volume":"36","author":"Bouhajib","year":"2025","journal-title":"J Basic Clin Physiol Pharmacol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib126","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s40618-024-02369-4","article-title":"Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?","volume":"47","author":"Formichi","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib127","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1210\/jc.2008-1518","article-title":"Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes","volume":"93","author":"Matthews","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib129","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.2337\/diabetes.53.9.2492","article-title":"A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis","volume":"53","author":"Baggio","year":"2004","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2026.100150_bib130","first-page":"229","article-title":"Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes","volume":"7","author":"Mann","year":"2014","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib131","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jdiacomp.2013.12.009","article-title":"Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes","volume":"28","author":"Henry","year":"2014","journal-title":"J Diabetes Complications"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib132","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1021\/acsptsci.4c00173","article-title":"GLP-1 analogue-loaded glucose-responsive nanoparticles as allies of stem cell therapies for the treatment of type i diabetes","volume":"7","author":"Marques","year":"2024","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib133","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1080\/1061186X.2021.1894434","article-title":"Role of lipid nanocarriers for enhancing oral absorption and bioavailability of insulin and GLP-1 receptor agonists","volume":"29","author":"Poudwal","year":"2021","journal-title":"J Drug Target"},{"key":"10.1016\/j.pharmr.2026.100150_bib134","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/DMSO.S141235","article-title":"Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes","volume":"10","author":"Sikirica","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib135","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"47","key":"10.1016\/j.pharmr.2026.100150_bib136","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"778","key":"10.1016\/j.pharmr.2026.100150_bib137","doi-asserted-by":"crossref","first-page":"eadp5765","DOI":"10.1126\/scitranslmed.adp5765","article-title":"The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron","volume":"16","author":"Sloop","year":"2024","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib138","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib139","doi-asserted-by":"crossref","first-page":"8208","DOI":"10.1021\/acs.jmedchem.1c01856","article-title":"A small-molecule oral agonist of the human glucagon-like peptide-1 receptor","volume":"65","author":"Griffith","year":"2022","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib140","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib141","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1111\/dom.15168","article-title":"Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: a 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes","volume":"25","author":"Saxena","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib143","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib144","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib145","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.pharmr.2026.100150_bib146","article-title":"Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron","year":"2023","journal-title":"Adults with Obesity"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib147","doi-asserted-by":"crossref","DOI":"10.2337\/db25-865-P","article-title":"865-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1RA in Chinese Obese Adults without Diabetes","volume":"74","author":"Gu","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2026.100150_bib148","series-title":"Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity","year":"2024"},{"key":"10.1016\/j.pharmr.2026.100150_bib149","series-title":"Structure Therapeutics Reports Positive Topline Data from its Phase 2a Obesity Study and Capsule to Tablet PK Study for its Oral Non-Peptide Small Molecule GLP-1 Receptor Agonist GSBR-1290","year":"2024"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib150","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100150_bib151","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N Engl J Med"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib153","doi-asserted-by":"crossref","DOI":"10.2337\/db24-1861-LB","article-title":"1861-LB: Efficacy and Safety of HRS9531, a Novel Dual GLP-1\/GIP Receptor Agonist, in Obese Adults\u2014A Phase 2 Trial","volume":"73","author":"Zhao","year":"2024","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib154","doi-asserted-by":"crossref","DOI":"10.2337\/db25-853-P","article-title":"853-P: Efficacy and Safety of a Novel Dual GLP-1\/GIP Receptor Agonist (HRS9531), in Obese Adults without Diabetes\u2014Up to 52-Week Treatment","volume":"74","author":"Zhao","year":"2025","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib155","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib156","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"issue":"9861","key":"10.1016\/j.pharmr.2026.100150_bib157","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib158","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib159","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","article-title":"Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial","volume":"6","author":"Pratley","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib161","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib162","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib163","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib164","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100150_bib165","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"issue":"10192","key":"10.1016\/j.pharmr.2026.100150_bib166","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib167","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib168","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib169","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib170","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diabetes Care"},{"issue":"9951","key":"10.1016\/j.pharmr.2026.100150_bib171","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib172","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"issue":"9683","key":"10.1016\/j.pharmr.2026.100150_bib173","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib174","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib175","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","article-title":"Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial","volume":"67","author":"Bluher","year":"2024","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib176","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"issue":"10295","key":"10.1016\/j.pharmr.2026.100150_bib177","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib178","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Frias","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib179","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eprac.2024.05.005","article-title":"Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment","volume":"30","author":"Jabbour","year":"2024","journal-title":"Endocr Pract"},{"issue":"10401","key":"10.1016\/j.pharmr.2026.100150_bib180","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmr.2026.100150_bib181","series-title":"FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes","year":"2024"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib182","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib183","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Helmstadter","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmr.2026.100150_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108667","article-title":"Glucagon-like peptide-1 attenuates endothelial barrier injury in diabetes via cAMP\/PKA mediated down-regulation of MLC phosphorylation","volume":"113","author":"Tang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.pharmr.2026.100150_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2023.102355","article-title":"The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms","volume":"69","author":"Ribeiro-Silva","year":"2023","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib186","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib187","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/dom.12884","article-title":"Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: a sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial","volume":"19","author":"von Scholten","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib188","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib189","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib190","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurjpc\/zwaa081","article-title":"Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes","volume":"28","author":"Longato","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100150_bib191","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100150_bib192","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib193","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10193","key":"10.1016\/j.pharmr.2026.100150_bib194","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100150_bib195","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100150_bib196","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib197","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"issue":"10157","key":"10.1016\/j.pharmr.2026.100150_bib198","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib199","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"Chronic kidney disease and risk management: standards of care in diabetes-2025","volume":"48","year":"2025","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib200","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1210\/jc.2003-031403","article-title":"Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men","volume":"89","author":"Gutzwiller","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib201","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1210\/clinem\/dgaa643","article-title":"The renal extraction and the natriuretic action of GLP-1 in humans depend on interaction with the GLP-1 receptor","volume":"106","author":"Asmar","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib202","doi-asserted-by":"crossref","first-page":"E664","DOI":"10.1210\/jc.2012-3855","article-title":"Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men","volume":"98","author":"Skov","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100150_bib203","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13503","article-title":"Glucagon-like peptide-1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP-1 receptors","volume":"5","author":"Ronn","year":"2017","journal-title":"Physiol Rep"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib204","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/s41440-018-0070-0","article-title":"Simultaneous GLP-1 receptor activation and angiotensin receptor blockade increase natriuresis independent of altered arterial pressure in obese OLETF rats","volume":"41","author":"Rodriguez","year":"2018","journal-title":"Hypertens Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib205","doi-asserted-by":"crossref","first-page":"F867","DOI":"10.1152\/ajprenal.00527.2014","article-title":"Activation of GLP-1 receptors on vascular smooth muscle cells reduces the autoregulatory response in afferent arterioles and increases renal blood flow","volume":"308","author":"Jensen","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib206","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13102","article-title":"Acute effects of glucagon-like peptide-1, GLP-1(9-36 amide), and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers","volume":"5","author":"Bremholm","year":"2017","journal-title":"Physiol Rep"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib207","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib208","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jdiacomp.2015.04.004","article-title":"Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes","volume":"29","author":"von Scholten","year":"2015","journal-title":"J Diabetes Complications"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib209","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1111\/dom.13668","article-title":"Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7)","volume":"21","author":"Tuttle","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100150_bib210","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib211","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","article-title":"GLP-1 receptor agonists' impact on cardio-renal outcomes and mortality in T2D with acute kidney disease","volume":"15","author":"Pan","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib212","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib213","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.2337\/db14-0263","article-title":"SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis","volume":"63","author":"Xu","year":"2014","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib214","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1002\/hep.30320","article-title":"Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"69","author":"Yan","year":"2019","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib215","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.pharmr.2026.100150_bib216","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib217","first-page":"407","article-title":"Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: the lira-NAFLD study","volume":"102","author":"Petit","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib218","article-title":"Liraglutide decreases liver fat content and serum fibroblast growth factor 21 levels in newly diagnosed overweight patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"2021","author":"Li","year":"2021","journal-title":"J Diabetes Res"},{"issue":"10019","key":"10.1016\/j.pharmr.2026.100150_bib219","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib221","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib222","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib223","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib224","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2024.02.022","article-title":"Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH\/MASH and Type 2 Diabetes in a Randomized Phase 2 Study","volume":"23","author":"Harrison","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib226","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1021\/acschemneuro.7b00410","article-title":"Advanced glycation end products modulate amyloidogenic app processing and tau phosphorylation: a mechanistic link between glycation and the development of Alzheimer's disease","volume":"9","author":"Batkulwar","year":"2018","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib227","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib228","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","article-title":"Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles","volume":"14","author":"Meade","year":"2019","journal-title":"Mol Neurodegener"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib229","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1530\/EJE-19-0259","article-title":"Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case-control study","volume":"181","author":"Wium-Andersen","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib230","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib231","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamaneurol.2025.0353","article-title":"GLP-1RA and SGLT2i medications for type 2 diabetes and Alzheimer disease and related dementias","volume":"82","author":"Tang","year":"2025","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib232","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13195-024-01573-x","article-title":"Inflammatory proteins associated with Alzheimer's disease reduced by a GLP1 receptor agonist: a post hoc analysis of the EXSCEL randomized placebo controlled trial","volume":"16","author":"Koychev","year":"2024","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib233","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1567205016666190913155950","article-title":"A pilot study of exenatide actions in Alzheimer's disease","volume":"16","author":"Mullins","year":"2019","journal-title":"Curr Alzheimer Res"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib234","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1007\/s40618-024-02320-7","article-title":"Long-acting exenatide does not prevent cognitive decline in mild cognitive impairment: a proof-of-concept clinical trial","volume":"47","author":"Dei Cas","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100150_bib235","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of lixisenatide in early Parkinson\u2019s disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N Engl J Med"},{"issue":"10479","key":"10.1016\/j.pharmr.2026.100150_bib236","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib237","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol"},{"issue":"10103","key":"10.1016\/j.pharmr.2026.100150_bib238","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib239","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cmet.2020.10.023","article-title":"GDF-15 neutralization alleviates platinum-based chemotherapy-induced emesis, anorexia, and weight loss in mice and nonhuman primates","volume":"32","author":"Breen","year":"2020","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib240","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1210\/clinem\/dgad471","article-title":"Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: an updated systematic review and meta-analysis","volume":"109","author":"Park","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib241","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","article-title":"One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib242","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamaoto.2024.4852","article-title":"GLP-1RA use and thyroid cancer risk","volume":"151","author":"Brito","year":"2025","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib243","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/jcm14030944","article-title":"Pancreatitis risk associated with GLP-1 receptor agonists, considered as a single class, in a comorbidity-free subgroup of type 2 diabetes patients in the United States: a propensity score-matched analysis","volume":"14","author":"Ayoub","year":"2025","journal-title":"J Clin Med"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100150_bib244","doi-asserted-by":"crossref","first-page":"11050","DOI":"10.1074\/jbc.M601203200","article-title":"Prohormone convertase 1\/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor","volume":"281","author":"Ugleholdt","year":"2006","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib245","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1053\/j.gastro.2010.01.049","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion","volume":"138","author":"Fujita","year":"2010","journal-title":"Gastroenterology"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib246","doi-asserted-by":"crossref","DOI":"10.2337\/db19-1976-P","article-title":"1976-P: physiological effects of GIP(1-30)NH2 in healthy subjects","volume":"68","author":"Krogh","year":"2019","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib247","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/bph.13384","article-title":"N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor","volume":"173","author":"Hansen","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib248","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2337\/diab.27.3.327","article-title":"Effects of ingestion of triglyceride or galactose on secretion of gastric inhibitory polypeptide and on responses to intravenous glucose in normal and diabetic subjects","volume":"27","author":"Ross","year":"1978","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib249","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.2337\/db08-0307","article-title":"Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion","volume":"57","author":"Edfalk","year":"2008","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib250","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/en.2014-1653","article-title":"Free fatty acid receptor GPR120 is highly expressed in enteroendocrine K cells of the upper small intestine and has a critical role in GIP secretion after fat ingestion","volume":"156","author":"Iwasaki","year":"2015","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib251","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00125-008-1202-x","article-title":"Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells","volume":"52","author":"Parker","year":"2009","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib252","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/endo.133.6.8243312","article-title":"Gastric inhibitory polypeptide receptor, a member of the secretin- vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain","volume":"133","author":"Usdin","year":"1993","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib253","doi-asserted-by":"crossref","first-page":"906","DOI":"10.2337\/db18-1123","article-title":"Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals","volume":"68","author":"Gasbjerg","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2026.100150_bib254","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016334","article-title":"Genetic and biased agonist-mediated reductions in beta-arrestin recruitment prolong cAMP signaling at glucagon family receptors","volume":"296","author":"Jones","year":"2021","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/dom.12181","article-title":"A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents","volume":"16","author":"Tatarkiewicz","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib256","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/s42255-024-01061-4","article-title":"Characterization of genetic variants of GIPR reveals a contribution of beta-arrestin to metabolic phenotypes","volume":"6","author":"Kizilkaya","year":"2024","journal-title":"Nat Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib257","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib258","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.2337\/db06-1033","article-title":"Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes","volume":"56","author":"Xu","year":"2007","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib259","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1530\/EC-19-0144","article-title":"GIP-induced vasodilation in human adipose tissue involves capillary recruitment","volume":"8","author":"Asmar","year":"2019","journal-title":"Endocr Connect"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib260","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1194\/jlr.M006841","article-title":"GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene","volume":"51","author":"Kim","year":"2010","journal-title":"J Lipid Res"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib261","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.2337\/db10-0098","article-title":"Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans","volume":"59","author":"Asmar","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib262","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00100.2012","article-title":"Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes","volume":"304","author":"Timper","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib263","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1096\/fj.11-196782","article-title":"Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes","volume":"26","author":"Nie","year":"2012","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmr.2026.100150_bib264","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2025.102118","article-title":"Glucose-dependent insulinotropic polypeptide (GIP)","volume":"95","author":"Muller","year":"2025","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib265","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00125-018-4810-0","article-title":"Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight\/obese individuals: a randomised, crossover study","volume":"62","author":"Bergmann","year":"2019","journal-title":"Diabetologia"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib266","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib267","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101407","article-title":"Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation","volume":"55","author":"Costa","year":"2022","journal-title":"Mol Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib268","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.2337\/db21-0848","article-title":"GIPR agonism inhibits PYY-induced nausea-like behavior","volume":"71","author":"Samms","year":"2022","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2026.100150_bib269","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101743","article-title":"GIP receptor agonism blocks chemotherapy-induced nausea and vomiting","volume":"73","author":"Borner","year":"2023","journal-title":"Mol Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib270","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.2337\/db21-0459","article-title":"GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models","volume":"70","author":"Borner","year":"2021","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib271","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/s42255-023-00931-7","article-title":"Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice","volume":"5","author":"Liskiewicz","year":"2023","journal-title":"Nat Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib272","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ejendo\/lvac004","article-title":"GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells","volume":"188","author":"Hansen","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.pharmr.2026.100150_bib273","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2019.115079","article-title":"GIP's effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH(2)","volume":"130","author":"Gasbjerg","year":"2020","journal-title":"Bone"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib274","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.cmet.2017.11.003","article-title":"Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction","volume":"27","author":"Ussher","year":"2018","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib275","doi-asserted-by":"crossref","first-page":"E773","DOI":"10.1152\/ajpendo.00507.2003","article-title":"Glucose-dependent insulinotropic peptide: differential effects on hepatic artery vs. portal vein endothelial cells","volume":"286","author":"Ding","year":"2004","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib276","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2337\/db15-0122","article-title":"Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB","volume":"65","author":"Berglund","year":"2016","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib277","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1210\/en.2018-00336","article-title":"Glucose-Dependent Insulinotropic Polypeptide Suppresses Peripheral Arterial Remodeling in Male Mice","volume":"159","author":"Mori","year":"2018","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib278","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1055\/s-0032-1312595","article-title":"Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its antioxidative properties","volume":"44","author":"Ojima","year":"2012","journal-title":"Horm Metab Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib279","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s42255-025-01294-x","article-title":"GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice","volume":"7","author":"Gutgesell","year":"2025","journal-title":"Nat Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib280","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2337\/db23-0172","article-title":"GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice","volume":"73","author":"Furber","year":"2024","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib281","doi-asserted-by":"crossref","first-page":"652","DOI":"10.2337\/diabetes.51.3.652","article-title":"Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats","volume":"51","author":"Hinke","year":"2002","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib282","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/jm0509997","article-title":"GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential","volume":"49","author":"Irwin","year":"2006","journal-title":"J Med Chem"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib283","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1016\/j.bbagen.2013.03.011","article-title":"A novel acylated form of (d-Ala(2))GIP with improved antidiabetic potential, lacking effect on body fat stores","volume":"1830","author":"Martin","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib284","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1172\/JCI25483","article-title":"Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure","volume":"117","author":"Hansotia","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib285","doi-asserted-by":"crossref","first-page":"190","DOI":"10.2337\/db07-1202","article-title":"Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice","volume":"57","author":"Lamont","year":"2008","journal-title":"Diabetes"},{"issue":"2-3","key":"10.1016\/j.pharmr.2026.100150_bib286","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejphar.2010.10.059","article-title":"Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice","volume":"650","author":"Porter","year":"2011","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib287","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.peptides.2011.02.011","article-title":"Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight","volume":"32","author":"Szalowska","year":"2011","journal-title":"Peptides"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100150_bib288","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.regpep.2006.03.006","article-title":"Biological activity and antidiabetic potential of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide, GIP(1-16) and (Pro3)GIP(1-16)","volume":"135","author":"Irwin","year":"2006","journal-title":"Regul Pept"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib289","doi-asserted-by":"crossref","DOI":"10.2337\/db23-56-OR","article-title":"56-OR: A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting","volume":"72","author":"Knop","year":"2023","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib290","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1111\/dom.15875","article-title":"A long-acting glucose-dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon-like peptide-1 receptor agonist therapy","volume":"26","author":"Knop","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib291","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.686","article-title":"Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index","volume":"42","author":"Speliotes","year":"2010","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib292","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/ng.521","article-title":"Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge","volume":"42","author":"Saxena","year":"2010","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib293","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nm727","article-title":"Inhibition of gastric inhibitory polypeptide signaling prevents obesity","volume":"8","author":"Miyawaki","year":"2002","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib294","doi-asserted-by":"crossref","first-page":"E835","DOI":"10.1152\/ajpendo.00646.2020","article-title":"GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism","volume":"320","author":"Boer","year":"2021","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib295","doi-asserted-by":"crossref","first-page":"868","DOI":"10.2337\/db16-0758","article-title":"Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice","volume":"66","author":"Joo","year":"2017","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib296","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/bph.13323","article-title":"Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors","volume":"173","author":"Sparre-Ulrich","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib297","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1515\/BC.2007.019","article-title":"Characterisation and glucoregulatory actions of a novel acylated form of the (Pro3)GIP receptor antagonist in type 2 diabetes","volume":"388","author":"Gault","year":"2007","journal-title":"Biol Chem"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib298","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1006\/bbrc.2002.6364","article-title":"Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide","volume":"290","author":"Gault","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib299","doi-asserted-by":"crossref","first-page":"E1746","DOI":"10.1152\/ajpendo.00460.2007","article-title":"GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet","volume":"293","author":"McClean","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib300","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00125-017-4447-4","article-title":"GIP(3-30)NH(2) is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study","volume":"61","author":"Gasbjerg","year":"2018","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib301","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.2337\/db17-0480","article-title":"The Gluco- and Liporegulatory and Vasodilatory Effects of Glucose-Dependent Insulinotropic Polypeptide (GIP) Are Abolished by an Antagonist of the Human GIP Receptor","volume":"66","author":"Asmar","year":"2017","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib302","doi-asserted-by":"crossref","first-page":"e725","DOI":"10.1210\/clinem\/dgz175","article-title":"GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals","volume":"105","author":"Gasbjerg","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib303","doi-asserted-by":"crossref","first-page":"492","DOI":"10.3389\/fendo.2019.00492","article-title":"Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats","volume":"10","author":"Baldassano","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib304","doi-asserted-by":"crossref","DOI":"10.2337\/db22-357-OR","article-title":"357-OR: Improved Glycemic Control in Persons with Type 2 Diabetes Improves Beta-Cell Actions of Endogenous Glucose-Dependent Insulinotropic Polypeptide","volume":"71","author":"Hoe","year":"2022","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib305","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1530\/EJE-21-0135","article-title":"Effects of endogenous GIP in patients with type 2 diabetes","volume":"185","author":"Stensen","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"27","key":"10.1016\/j.pharmr.2026.100150_bib306","doi-asserted-by":"crossref","first-page":"19760","DOI":"10.1074\/jbc.M112.426288","article-title":"Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor","volume":"288","author":"Ravn","year":"2013","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib307","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1172\/JCI126107","article-title":"Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition","volume":"129","author":"Kaneko","year":"2019","journal-title":"J Clin Invest"},{"issue":"472","key":"10.1016\/j.pharmr.2026.100150_bib308","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat3392","article-title":"Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models","volume":"10","author":"Killion","year":"2018","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib309","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1463-1326.2011.01555.x","article-title":"Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo","volume":"14","author":"Nakamura","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib310","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/osp4.164","article-title":"Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice","volume":"4","author":"Nakamura","year":"2018","journal-title":"Obes Sci Pract"},{"key":"10.1016\/j.pharmr.2026.100150_bib311","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/DMSO.S297353","article-title":"GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice","volume":"14","author":"Nakamura","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib312","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0167-4781(00)00067-1","article-title":"Identification of a novel FGF, FGF-21, preferentially expressed in the liver","volume":"1492","author":"Nishimura","year":"2000","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib313","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1128\/MCB.02249-06","article-title":"Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members","volume":"27","author":"Goetz","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib314","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J Clin Invest"},{"issue":"37","key":"10.1016\/j.pharmr.2026.100150_bib315","doi-asserted-by":"crossref","first-page":"26687","DOI":"10.1074\/jbc.M704165200","article-title":"Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21","volume":"282","author":"Kurosu","year":"2007","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib316","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1210\/me.2007-0313","article-title":"betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c","volume":"22","author":"Suzuki","year":"2008","journal-title":"Mol Endocrinol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib317","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.febslet.2008.11.023","article-title":"FGF21 N- and C-termini play different roles in receptor interaction and activation","volume":"583","author":"Yie","year":"2009","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib318","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jcp.21675","article-title":"Different roles of N- and C- termini in the functional activity of FGF21","volume":"219","author":"Micanovic","year":"2009","journal-title":"J Cell Physiol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib319","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.celrep.2016.08.086","article-title":"mTORC1 Is a Major Regulatory Node in the FGF21 Signaling Network in Adipocytes","volume":"17","author":"Minard","year":"2016","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib320","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.2337\/db05-1435","article-title":"Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1\/2 and Akt signaling pathways","volume":"55","author":"Wente","year":"2006","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib321","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00109-016-1477-1","article-title":"FGF21 activates AMPK signaling: impact on metabolic regulation and the aging process","volume":"95","author":"Salminen","year":"2017","journal-title":"J Mol Med (Berl)"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib322","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.28523","article-title":"Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice","volume":"64","author":"Gong","year":"2016","journal-title":"Hepatology"},{"issue":"Pt 1","key":"10.1016\/j.pharmr.2026.100150_bib323","article-title":"Fibroblast growth factor 21 alleviates idiopathic pulmonary fibrosis by inhibiting PI3K-AKT-mTOR signaling and stimulating autophagy","volume":"273","author":"Qi","year":"2024","journal-title":"Int J Biol Macromol"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100150_bib324","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0904187106","article-title":"FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response","volume":"106","author":"Potthoff","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib325","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","article-title":"Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21","volume":"5","author":"Inagaki","year":"2007","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib326","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.2337\/db14-0595","article-title":"Circulating FGF21 is liver derived and enhances glucose uptake during refeeding and overfeeding","volume":"63","author":"Markan","year":"2014","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib327","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1042\/BJ20111748","article-title":"Activating transcription factor 4-dependent induction of FGF21 during amino acid deprivation","volume":"443","author":"De Sousa-Coelho","year":"2012","journal-title":"Biochem J"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib328","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","article-title":"Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states","volume":"5","author":"Badman","year":"2007","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib329","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cmet.2016.09.001","article-title":"Defining the Nutritional and Metabolic Context of FGF21 Using the Geometric Framework","volume":"24","author":"Solon-Biet","year":"2016","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0063517","article-title":"Acute exercise induces FGF21 expression in mice and in healthy humans","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"issue":"7-8","key":"10.1016\/j.pharmr.2026.100150_bib331","doi-asserted-by":"crossref","first-page":"736","DOI":"10.2119\/molmed.2011.00075","article-title":"Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21","volume":"17","author":"Chartoumpekis","year":"2011","journal-title":"Mol Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib332","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4093\/dmj.2014.38.4.245","article-title":"FGF21 as a Stress Hormone: The Roles of FGF21 in Stress Adaptation and the Treatment of Metabolic Diseases","volume":"38","author":"Kim","year":"2014","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.pharmr.2026.100150_bib333","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-pharmtox-032322-093904","article-title":"Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications","volume":"63","author":"Jin","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib334","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1055\/a-0879-2968","article-title":"Circulating FGF21 Levels in Human Health and Metabolic Disease","volume":"128","author":"Keuper","year":"2020","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib335","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1210\/en.2012-1193","article-title":"TNF-alpha represses beta-Klotho expression and impairs FGF21 action in adipose cells: involvement of JNK1 in the FGF21 pathway","volume":"153","author":"Diaz-Delfin","year":"2012","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib336","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.2337\/db13-0645","article-title":"High glucose represses beta-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor gamma signaling","volume":"62","author":"So","year":"2013","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib337","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0126364","article-title":"Ketogenic Diet Impairs FGF21 Signaling and Promotes Differential Inflammatory Responses in the Liver and White Adipose Tissue","volume":"10","author":"Asrih","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2026.100150_bib338","doi-asserted-by":"crossref","DOI":"10.1038\/s43587-025-00813-5","article-title":"Enhanced paracrine action of FGF21 in stromal cells delays thymic aging","author":"Youm","year":"2025","journal-title":"Nat Aging"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib339","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s12640-019-00151-6","article-title":"FGF21 Protects Dopaminergic Neurons in Parkinson's Disease Models Via Repression of Neuroinflammation","volume":"37","author":"Fang","year":"2020","journal-title":"Neurotox Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib340","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1007\/s12035-017-0663-7","article-title":"FGF21 Attenuates High-Fat Diet-Induced Cognitive Impairment via Metabolic Regulation and Anti-inflammation of Obese Mice","volume":"55","author":"Wang","year":"2018","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.pharmr.2026.100150_bib341","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.yhbeh.2016.08.006","article-title":"FGF21 improves cognition by restored synaptic plasticity, dendritic spine density, brain mitochondrial function and cell apoptosis in obese-insulin resistant male rats","volume":"85","author":"Sa-Nguanmoo","year":"2016","journal-title":"Horm Behav"},{"key":"10.1016\/j.pharmr.2026.100150_bib342","article-title":"FGF21 ameliorates diabetic nephropathy through CDK1-dependently regulating the cell cycle","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib343","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/15548627.2023.2259282","article-title":"FGF21 and autophagy coordinately counteract kidney disease progression during aging and obesity","volume":"20","author":"Minami","year":"2024","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib344","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12551","article-title":"FGF21 attenuates high uric acid-induced endoplasmic reticulum stress, inflammation and vascular endothelial cell dysfunction by activating Sirt1","volume":"25","author":"Ouyang","year":"2022","journal-title":"Mol Med Rep"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib345","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bcpt.13793","article-title":"Fibroblast growth factor 21 attenuates the progression of hyperuricemic nephropathy through inhibiting inflammation, fibrosis and oxidative stress","volume":"131","author":"Jiang","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib346","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/mc.20241","article-title":"Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis","volume":"45","author":"Huang","year":"2006","journal-title":"Mol Carcinog"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib347","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1016\/j.peptides.2007.10.007","article-title":"The fasting polypeptide FGF21 can enter brain from blood","volume":"28","author":"Hsuchou","year":"2007","journal-title":"Peptides"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib348","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.3249","article-title":"FGF21 regulates metabolism and circadian behavior by acting on the nervous system","volume":"19","author":"Bookout","year":"2013","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib349","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/db09-1878","article-title":"Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats","volume":"59","author":"Sarruf","year":"2010","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib350","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cmet.2014.07.012","article-title":"FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss","volume":"20","author":"Owen","year":"2014","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib351","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.cmet.2017.09.005","article-title":"FGF19, FGF21, and an FGFR1\/beta-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia","volume":"26","author":"Lan","year":"2017","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib352","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s12576-018-0595-7","article-title":"Effects of central FGF21 infusion on the hypothalamus-pituitary-thyroid axis and energy metabolism in rats","volume":"68","author":"Yilmaz","year":"2018","journal-title":"J Physiol Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib353","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1210\/en.2014-2001","article-title":"Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice","volume":"156","author":"Douris","year":"2015","journal-title":"Endocrinology"},{"issue":"3 Pt 1","key":"10.1016\/j.pharmr.2026.100150_bib354","first-page":"E255","article-title":"Effects of corticotropin-releasing factor on food intake and brown adipose tissue thermogenesis in rats","volume":"255","author":"Arase","year":"1988","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib355","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.neuroscience.2006.02.027","article-title":"Corticotropin releasing factor increases in brown adipose tissue thermogenesis and heart rate through dorsomedial hypothalamus and medullary raphe pallidus","volume":"140","author":"Cerri","year":"2006","journal-title":"Neuroscience"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib356","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/0028-3908(87)90272-3","article-title":"Activation of brown fat thermogenesis in response to central injection of corticotropin releasing hormone in the rat","volume":"26","author":"LeFeuvre","year":"1987","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib357","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.cmet.2023.02.005","article-title":"FGF21 counteracts alcohol intoxication by activating the noradrenergic nervous system","volume":"35","author":"Choi","year":"2023","journal-title":"Cell Metab"},{"issue":"D1","key":"10.1016\/j.pharmr.2026.100150_bib358","doi-asserted-by":"crossref","first-page":"D746","DOI":"10.1093\/nar\/gkv1045","article-title":"Expression Atlas update--an integrated database of gene and protein expression in humans, animals and plants","volume":"44","author":"Petryszak","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib359","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040164","article-title":"FGF21 promotes metabolic homeostasis via white adipose and leptin in mice","volume":"7","author":"Veniant","year":"2012","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib360","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.2337\/db16-0327","article-title":"FGF21 Improves the Adipocyte Dysfunction Related to Seipin Deficiency","volume":"65","author":"Dollet","year":"2016","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib361","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.molmet.2012.08.007","article-title":"The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue","volume":"2","author":"Adams","year":"2012","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib362","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2012.08.002","article-title":"betaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism","volume":"16","author":"Ding","year":"2012","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib363","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049977","article-title":"FGF21 requires betaklotho to act in vivo","volume":"7","author":"Adams","year":"2012","journal-title":"PLoS One"},{"issue":"113","key":"10.1016\/j.pharmr.2026.100150_bib364","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002669","article-title":"Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1","volume":"3","author":"Wu","year":"2011","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib365","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.cmet.2017.03.005","article-title":"FGF21 Regulates Metabolism Through Adipose-Dependent and -Independent Mechanisms","volume":"25","author":"BonDurant","year":"2017","journal-title":"Cell Metab"},{"issue":"40","key":"10.1016\/j.pharmr.2026.100150_bib366","doi-asserted-by":"crossref","first-page":"34533","DOI":"10.1074\/jbc.M111.248591","article-title":"Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor\/Ets-like protein-1 in adipocytes","volume":"286","author":"Ge","year":"2011","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib367","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","article-title":"FGF21 Lowers Plasma Triglycerides by Accelerating Lipoprotein Catabolism in White and Brown Adipose Tissues","volume":"23","author":"Schlein","year":"2016","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib368","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.febslet.2008.04.038","article-title":"FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity","volume":"582","author":"Arner","year":"2008","journal-title":"FEBS Lett"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100150_bib369","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.febslet.2009.09.012","article-title":"Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob\/ob mice","volume":"583","author":"Li","year":"2009","journal-title":"FEBS Lett"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib370","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.cmet.2013.03.019","article-title":"An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice","volume":"17","author":"Holland","year":"2013","journal-title":"Cell Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib371","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.cmet.2013.04.005","article-title":"Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice","volume":"17","author":"Lin","year":"2013","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib372","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1172\/JCI29126","article-title":"Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome","volume":"116","author":"Kadowaki","year":"2006","journal-title":"J Clin Invest"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100150_bib373","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cca.2007.01.026","article-title":"Adiponectin as an anti-inflammatory factor","volume":"380","author":"Ouchi","year":"2007","journal-title":"Clin Chim Acta"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib374","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.cmet.2016.02.001","article-title":"A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects","volume":"23","author":"Talukdar","year":"2016","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib375","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.cmet.2013.08.005","article-title":"The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes","volume":"18","author":"Gaich","year":"2013","journal-title":"Cell Metab"},{"issue":"10165","key":"10.1016\/j.pharmr.2026.100150_bib376","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib377","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1111\/dom.13023","article-title":"Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates","volume":"19","author":"Kim","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib378","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/oby.22344","article-title":"Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study","volume":"27","author":"Charles","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib379","article-title":"AKR-001, an Fc-FGF21 Analog, Showed Sustained Pharmacodynamic Effects on Insulin Sensitivity and Lipid Metabolism in Type 2 Diabetes Patients","volume":"1","author":"Kaufman","year":"2020","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib380","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1210\/clinem\/dgab624","article-title":"LLF580, an FGF21 Analog, Reduces Triglycerides and Hepatic Fat in Obese Adults With Modest Hypertriglyceridemia","volume":"107","author":"Rader","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib381","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/hep.32742","article-title":"Fibroblast growth factor receptor 1\/Klothobeta agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial","volume":"78","author":"Wong","year":"2023","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100150_bib382","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1161\/CIRCULATIONAHA.115.015308","article-title":"Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice","volume":"131","author":"Lin","year":"2015","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100150_bib383","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1111\/bph.14383","article-title":"A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway","volume":"175","author":"Bao","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib384","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1101\/gad.177857.111","article-title":"FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis","volume":"26","author":"Fisher","year":"2012","journal-title":"Genes Dev"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib385","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cmet.2017.08.003","article-title":"The FGF21-CCL11 Axis Mediates Beiging of White Adipose Tissues by Coupling Sympathetic Nervous System to Type 2 Immunity","volume":"26","author":"Huang","year":"2017","journal-title":"Cell Metab"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib386","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.celrep.2015.10.021","article-title":"FGF21-Mediated Improvements in Glucose Clearance Require Uncoupling Protein 1","volume":"13","author":"Kwon","year":"2015","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib387","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cmet.2015.04.019","article-title":"Pharmacologic Effects of FGF21 Are Independent of the \"Browning\" of White Adipose Tissue","volume":"21","author":"Veniant","year":"2015","journal-title":"Cell Metab"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib388","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.celrep.2015.04.046","article-title":"Discrete Aspects of FGF21 In Vivo Pharmacology Do Not Require UCP1","volume":"11","author":"Samms","year":"2015","journal-title":"Cell Rep"},{"issue":"28","key":"10.1016\/j.pharmr.2026.100150_bib389","doi-asserted-by":"crossref","first-page":"12553","DOI":"10.1073\/pnas.1006962107","article-title":"Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway","volume":"107","author":"Chau","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib390","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.cmet.2018.04.002","article-title":"FGF21 Prevents Angiotensin II-Induced Hypertension and Vascular Dysfunction by Activation of ACE2\/Angiotensin-(1-7) Axis in Mice","volume":"27","author":"Pan","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib391","article-title":"Fibroblast growth factor 21 deficiency exacerbates chronic alcohol-induced hepatic steatosis and injury","volume":"6","author":"Liu","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2026.100150_bib392","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.molmet.2017.12.008","article-title":"Hepatic regulation of VLDL receptor by PPARbeta\/delta and FGF21 modulates non-alcoholic fatty liver disease","volume":"8","author":"Zarei","year":"2018","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib393","doi-asserted-by":"crossref","first-page":"8578","DOI":"10.1038\/s41467-024-52379-2","article-title":"FGF21 modulates immunometabolic homeostasis via the ALOX15\/15-HETE axis in early liver graft injury","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib394","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1210\/me.2010-0142","article-title":"Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse","volume":"24","author":"Fon Tacer","year":"2010","journal-title":"Mol Endocrinol"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100150_bib395","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mce.2011.05.003","article-title":"The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes","volume":"342","author":"Zhang","year":"2011","journal-title":"Mol Cell Endocrinol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib396","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cmet.2025.04.014","article-title":"FGF21 reverses MASH through coordinated actions on the CNS and liver","volume":"37","author":"Rose","year":"2025","journal-title":"Cell Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib397","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/jcmm.17144","article-title":"FGF21 alleviates acute liver injury by inducing the SIRT1-autophagy signalling pathway","volume":"26","author":"Yang","year":"2022","journal-title":"J Cell Mol Med"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib398","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41419-023-05842-9","article-title":"FGF21-FGFR1 controls mitochondrial homeostasis in cardiomyocytes by modulating the degradation of OPA1","volume":"14","author":"Yan","year":"2023","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib399","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41467-025-56885-9","article-title":"FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib400","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087102","article-title":"Novel insights into the cardio-protective effects of FGF21 in lean and obese rat hearts","volume":"9","author":"Patel","year":"2014","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100150_bib401","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1042\/CS20170271","article-title":"FGF21 ameliorates diabetic cardiomyopathy by activating the AMPK-paraoxonase 1 signaling axis in mice","volume":"131","author":"Wu","year":"2017","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib402","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/en.2006-1168","article-title":"The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21","volume":"148","author":"Kharitonenkov","year":"2007","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib403","doi-asserted-by":"crossref","first-page":"E1105","DOI":"10.1152\/ajpendo.00348.2009","article-title":"Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects","volume":"297","author":"Xu","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib404","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049345","article-title":"Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes","volume":"7","author":"Hecht","year":"2012","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib405","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tem.2024.02.001","article-title":"Current status and future perspectives of FGF21 analogues in clinical trials","volume":"35","author":"Chui","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib406","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0058575","article-title":"Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319","volume":"8","author":"Kharitonenkov","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib407","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/03639045.2022.2101062","article-title":"PEGylated drug delivery systems in the pharmaceutical field: past, present and future perspective","volume":"48","author":"Sanchez Armengol","year":"2022","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib408","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/13543784.2020.1708898","article-title":"Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis","volume":"29","author":"Verzijl","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib409","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.jacl.2020.05.067","article-title":"BIO89-100, a glycoPEGylated FGF21 analog, improved serum lipids and extended half-life in a controlled single ascending dose trial in healthy subjects","volume":"14","author":"Margalit","year":"2020","journal-title":"Journal of Clinical Lipidology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib410","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1124\/jpet.113.204420","article-title":"Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody","volume":"346","author":"Huang","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib411","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1210\/en.2016-1917","article-title":"A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward beta-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys","volume":"158","author":"Stanislaus","year":"2017","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmr.2026.100150_bib412","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(24)01561-7","volume":"80","author":"Bain","year":"2024","journal-title":"J Hepatol"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100150_bib413","doi-asserted-by":"crossref","first-page":"11769","DOI":"10.1021\/acs.jmedchem.4c00391","article-title":"Development of Zalfermin, a Long-Acting Proteolytically Stabilized FGF21 Analog","volume":"67","author":"Sass-Orum","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2026.100150_bib414","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jconrel.2024.11.006","article-title":"Lipidation-dimerization platform unlocks treatment potential of fibroblast growth factor 21 for non-alcoholic steatohepatitis","volume":"376","author":"Wang","year":"2024","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061432","article-title":"FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c\/beta-Klotho bispecific protein","volume":"8","author":"Smith","year":"2013","journal-title":"PLoS One"},{"issue":"162","key":"10.1016\/j.pharmr.2026.100150_bib416","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004690","article-title":"Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho\/FGFR1c receptor complex","volume":"4","author":"Foltz","year":"2012","journal-title":"Sci Transl Med"},{"issue":"38","key":"10.1016\/j.pharmr.2026.100150_bib417","doi-asserted-by":"crossref","first-page":"14678","DOI":"10.1074\/jbc.RA118.004343","article-title":"Agonistic beta-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions","volume":"293","author":"Min","year":"2018","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib418","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ebiom.2015.05.028","article-title":"Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1\/betaKlotho Complex","volume":"2","author":"Kolumam","year":"2015","journal-title":"EBioMedicine"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib419","doi-asserted-by":"crossref","DOI":"10.2337\/db19-140-LB","article-title":"140-LB: NGM313, a novel activator of b-Klotho\/FGFR1c, improves insulin resistance and reduces hepatic fat in obese, nondiabetic subjects","volume":"68","author":"Depaoli","year":"2019","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib420","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/apt.70038","article-title":"Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH","volume":"61","author":"Raji","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100150_bib421","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202401397R","article-title":"Therapeutic effects of FGF21 mimetic bFKB1 on MASH and atherosclerosis in Ldlr-\/-.Leiden mice","volume":"38","author":"Inia","year":"2024","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib422","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cgh.2023.04.011","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study","volume":"22","author":"Loomba","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib423","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cgh.2023.04.012","article-title":"Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study","volume":"22","author":"Abdelmalek","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib424","article-title":"A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis","volume":"5","author":"Harrison","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.pharmr.2026.100150_bib425","article-title":"Efruxifermin in compensated cirrhosis due to NASH\/MASH: results from a randomized, double-blind, placebo-controlled, phase 2b trial (SYMMETRY)","author":"Harrison","year":"2023","journal-title":"AASLD"},{"key":"10.1016\/j.pharmr.2026.100150_bib426","unstructured":"LOOMBA R, KOWDLEY K, RODRIGUEZ J, et al. Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in biomarkers of liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: A randomized, blinded, placebo-controlled Phase 2A trial."},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib427","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/cne.24668","article-title":"The central fibroblast growth factor receptor\/beta klotho system: Comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform","volume":"527","author":"Hultman","year":"2019","journal-title":"J Comp Neurol"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100150_bib428","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa0808718","article-title":"Cold-activated brown adipose tissue in healthy men","volume":"360","author":"van Marken Lichtenbelt","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib429","doi-asserted-by":"crossref","first-page":"E601","DOI":"10.1152\/ajpendo.00298.2010","article-title":"A critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humans","volume":"299","author":"Lee","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib430","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2337\/db07-1476","article-title":"Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans","volume":"57","author":"Zhang","year":"2008","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib431","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.2337\/db10-0193","article-title":"Obesity is a fibroblast growth factor 21 (FGF21)-resistant state","volume":"59","author":"Fisher","year":"2010","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib432","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cmet.2012.07.004","article-title":"Selective insulin and leptin resistance in metabolic disorders","volume":"16","author":"Konner","year":"2012","journal-title":"Cell Metab"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib433","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1016\/j.celrep.2019.02.014","article-title":"Exercise Alleviates Obesity-Induced Metabolic Dysfunction via Enhancing FGF21 Sensitivity in Adipose Tissues","volume":"26","author":"Geng","year":"2019","journal-title":"Cell Rep"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib434","doi-asserted-by":"crossref","first-page":"4084","DOI":"10.1210\/en.2009-0221","article-title":"Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity","volume":"150","author":"Berglund","year":"2009","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib435","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1530\/EC-19-0034","article-title":"Exercise ameliorates the FGF21-adiponectin axis impairment in diet-induced obese mice","volume":"8","author":"Yang","year":"2019","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib436","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/ijo.2014.76","article-title":"Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients","volume":"39","author":"Gallego-Escuredo","year":"2015","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib437","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2019-000776","article-title":"Plasma fibroblast growth factor 21 levels increase with ectopic fat accumulation and its receptor levels are decreased in the visceral fat of patients with type 2 diabetes","volume":"7","author":"Hong","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.pharmr.2026.100150_bib438","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3389\/fendo.2019.00566","article-title":"Improved FGF21 Sensitivity and Restored FGF21 Signaling Pathway in High-Fat Diet\/Streptozotocin-Induced Diabetic Rats After Duodenal-Jejunal Bypass and Sleeve Gastrectomy","volume":"10","author":"Liu","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib439","first-page":"277","article-title":"Diet Polyphenol Curcumin Stimulates Hepatic Fgf21 Production and Restores Its Sensitivity in High-Fat-Diet-Fed Male Mice","volume":"158","author":"Zeng","year":"2017","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib440","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/bcp.12676","article-title":"Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study","volume":"80","author":"Dong","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"4, Supplement","key":"10.1016\/j.pharmr.2026.100150_bib441","doi-asserted-by":"crossref","first-page":"e552","DOI":"10.1016\/j.jacl.2024.04.086","article-title":"Study Design of a Phase 3 Randomized Controlled Trial Evaluating the Efficacy and Safety of Pegozafermin in Patients with Severe Hypertriglyceridemia","volume":"18","author":"Hartsfield","year":"2024","journal-title":"Journal of Clinical Lipidology"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib442","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1503\/cmaj.060963","article-title":"Hypertriglyceridemia: its etiology, effects and treatment","volume":"176","author":"Yuan","year":"2007","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib443","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.bbrc.2007.06.068","article-title":"PPARalpha is a key regulator of hepatic FGF21","volume":"360","author":"Lundasen","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100150_bib444","doi-asserted-by":"crossref","first-page":"9175","DOI":"10.1074\/jbc.M116.767590","article-title":"The hepatokine FGF21 is crucial for peroxisome proliferator-activated receptor-alpha agonist-induced amelioration of metabolic disorders in obese mice","volume":"292","author":"Goto","year":"2017","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib445","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1007\/s10620-017-4812-7","article-title":"Identification and Characterization of Fenofibrate-Induced Liver Injury","volume":"62","author":"Ahmad","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib446","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/hep.27060","article-title":"Fibroblast growth factor 21 protects against acetaminophen-induced hepatotoxicity by potentiating peroxisome proliferator-activated receptor coactivator protein-1alpha-mediated antioxidant capacity in mice","volume":"60","author":"Ye","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib447","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051835","article-title":"The Diabetes Mellitus-Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation","volume":"21","author":"Poznyak","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib448","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/emmm.201200224","article-title":"Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease","volume":"4","author":"Besler","year":"2012","journal-title":"EMBO Mol Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib449","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1161\/01.ATV.0000219611.50066.bd","article-title":"Adiponectin is an important determinant of apoA-I catabolism","volume":"26","author":"Verges","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib450","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/apt.17709","article-title":"Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis","volume":"58","author":"Alkhouri","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100150_bib451","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2502242","article-title":"Efruxifermin in Compensated Liver Cirrhosis Caused by MASH","volume":"392","author":"Noureddin","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib452","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S2468-1253(25)00067-6","article-title":"Efimosfermin alfa (BOS-580), a long-acting FGF21 analogue, in participants with phenotypic metabolic dysfunction-associated steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial","volume":"10","author":"Loomba","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib453","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.4049\/jimmunol.1002060","article-title":"Adiponectin and heme oxygenase-1 suppress TLR4\/MyD88-independent signaling in rat Kupffer cells and in mice after chronic ethanol exposure","volume":"185","author":"Mandal","year":"2010","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib454","doi-asserted-by":"crossref","first-page":"G998","DOI":"10.1152\/ajpgi.00553.2005","article-title":"Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding","volume":"290","author":"Thakur","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib455","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1002\/hep.21991","article-title":"High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase","volume":"47","author":"Adachi","year":"2008","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib456","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1074\/jbc.M114.598011","article-title":"Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion","volume":"290","author":"Ramezani-Moghadam","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100150_bib457","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103249","article-title":"The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation","volume":"65","author":"Panera","year":"2021","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib458","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1007\/s11033-021-06707-0","article-title":"FGF21 ameliorates hepatic fibrosis by multiple mechanisms","volume":"48","author":"Meng","year":"2021","journal-title":"Mol Biol Rep"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib459","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1006\/cyto.1999.0485","article-title":"FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4","volume":"11","author":"Xie","year":"1999","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib460","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/joim.13767","article-title":"Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases","volume":"295","author":"Li","year":"2024","journal-title":"J Intern Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib461","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/ibd.21502","article-title":"Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers","volume":"17","author":"Lenicek","year":"2011","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib462","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cgh.2009.04.024","article-title":"A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis","volume":"7","author":"Walters","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib463","doi-asserted-by":"crossref","first-page":"627","DOI":"10.33549\/physiolres.932099","article-title":"Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-\u03b1 agonist treatment","volume":"60","author":"Mr\u00e1z","year":"2011","journal-title":"Physiol Res"},{"key":"10.1016\/j.pharmr.2026.100150_bib464","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13098-019-0475-1","article-title":"Serum fibroblast growth factor 19 and endogenous islet beta cell function in type 2 diabetic patients","volume":"11","author":"Tang","year":"2019","journal-title":"Diabetol Metab Syndr"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib465","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067160","article-title":"Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease","volume":"8","author":"Alisi","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib466","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.clinbiochem.2012.03.019","article-title":"Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"45","author":"Eren","year":"2012","journal-title":"Clin Biochem"},{"issue":"11-12","key":"10.1016\/j.pharmr.2026.100150_bib467","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1515\/jpem-2012-0253","article-title":"A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents","volume":"25","author":"Wojcik","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib468","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/s-0029-1243249","article-title":"Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters","volume":"42","author":"Reiche","year":"2010","journal-title":"Horm Metab Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib469","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1007\/s11695-019-03845-0","article-title":"Plasma FGF-19 Levels are Increased in Patients with Post-Bariatric Hypoglycemia","volume":"29","author":"Mulla","year":"2019","journal-title":"Obes Surg"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib470","doi-asserted-by":"crossref","DOI":"10.3390\/nu14030645","article-title":"Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass","volume":"14","author":"Guo","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib471","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1038\/s41467-021-24914-y","article-title":"Intestinal-derived FGF15 protects against deleterious effects of vertical sleeve gastrectomy in mice","volume":"12","author":"Bozadjieva-Kramer","year":"2021","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib472","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib473","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI23076","article-title":"Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho","volume":"115","author":"Ito","year":"2005","journal-title":"J Clin Invest"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100150_bib474","doi-asserted-by":"crossref","first-page":"17707","DOI":"10.1074\/jbc.M411771200","article-title":"Independent repression of bile acid synthesis and activation of c-Jun N-terminal kinase (JNK) by activated hepatocyte fibroblast growth factor receptor 4 (FGFR4) and bile acids","volume":"280","author":"Yu","year":"2005","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib475","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1101\/gad.184788.111","article-title":"Endocrine fibroblast growth factors 15\/19 and 21: from feast to famine","volume":"26","author":"Potthoff","year":"2012","journal-title":"Genes Dev"},{"issue":"6024","key":"10.1016\/j.pharmr.2026.100150_bib476","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis","volume":"331","author":"Kir","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pharmr.2026.100150_bib477","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101113","article-title":"FGF15\/19 is required for adipose tissue plasticity in response to thermogenic adaptations","volume":"43","author":"Mor\u00f3n-Ros","year":"2021","journal-title":"Mol Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib478","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","article-title":"FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1\u03b1 pathway","volume":"13","author":"Potthoff","year":"2011","journal-title":"Cell Metab"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib479","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2337\/db18-1305","article-title":"FGF19 Analog as a Surgical Factor Mimetic That Contributes to Metabolic Effects Beyond Glucose Homeostasis","volume":"68","author":"DePaoli","year":"2019","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib480","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1210\/endo.143.5.8850","article-title":"Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity","volume":"143","author":"Tomlinson","year":"2002","journal-title":"Endocrinology"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100150_bib481","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1042\/BCJ20180555","article-title":"Differential receptor selectivity of the FGF15\/FGF19 orthologues determines distinct metabolic activities in db\/db mice","volume":"475","author":"Hansen","year":"2018","journal-title":"Biochem J"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib482","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice","volume":"63","author":"Zhou","year":"2016","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib483","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/hep.29251","article-title":"Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice","volume":"66","author":"Slijepcevic","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib484","doi-asserted-by":"crossref","first-page":"G996","DOI":"10.1152\/ajpgi.90343.2008","article-title":"\u03b2-Klotho and FGF-15\/19 inhibit the apical sodium-dependent bile acid transporter in enterocytes and cholangiocytes","volume":"295","author":"Sinha","year":"2008","journal-title":"American Journal of Physiology-Gastrointestinal and Liver Physiology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib485","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1210\/en.2003-1671","article-title":"Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes","volume":"145","author":"Fu","year":"2004","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib486","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1248\/bpb.34.1885","article-title":"Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (Fxr)-null mice","volume":"34","author":"Miyata","year":"2011","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib487","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep4.1108","article-title":"Engineered FGF19 eliminates bile acid toxicity and lipotoxicity leading to resolution of steatohepatitis and fibrosis in mice","volume":"1","author":"Zhou","year":"2017","journal-title":"Hepatol Commun"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100150_bib488","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1074\/jbc.M808818200","article-title":"Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis","volume":"284","author":"Bhatnagar","year":"2009","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib489","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1136\/gutjnl-2016-312975","article-title":"Fibroblast growth factor 15\/19 (FGF15\/19) protects from diet-induced hepatic steatosis: development of an FGF19-based chimeric molecule to promote fatty liver regeneration","volume":"66","author":"Alvarez-Sola","year":"2017","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib490","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/hep.30810","article-title":"Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development","volume":"71","author":"Schumacher","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib491","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/hep.28709","article-title":"Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives","volume":"65","author":"Arab","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib492","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0033603","article-title":"Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism","volume":"7","author":"Ge","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib493","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1210\/en.2012-1891","article-title":"Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats","volume":"154","author":"Ryan","year":"2013","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib494","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1172\/JCI70710","article-title":"FGF19 action in the brain induces insulin-independent glucose lowering","volume":"123","author":"Morton","year":"2013","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib495","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.molmet.2013.10.002","article-title":"Central action of FGF19 reduces hypothalamic AGRP\/NPY neuron activity and improves glucose metabolism","volume":"3","author":"Marcelin","year":"2014","journal-title":"Mol Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib496","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1038\/ncomms7980","article-title":"FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis","volume":"6","author":"Perry","year":"2015","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib497","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1074\/jbc.M109.068783","article-title":"FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation","volume":"285","author":"Wu","year":"2010","journal-title":"J Biol Chem"},{"issue":"34","key":"10.1016\/j.pharmr.2026.100150_bib498","doi-asserted-by":"crossref","first-page":"14379","DOI":"10.1073\/pnas.0907812106","article-title":"Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob\/ob mice","volume":"106","author":"Wu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib499","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1194\/jlr.M027094","article-title":"Dual actions of fibroblast growth factor 19 on lipid metabolism","volume":"54","author":"Wu","year":"2013","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib500","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017868","article-title":"FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways","volume":"6","author":"Wu","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmr.2026.100150_bib501","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.molmet.2019.09.006","article-title":"The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis","volume":"30","author":"Antonellis","year":"2019","journal-title":"Mol Metab"},{"issue":"46","key":"10.1016\/j.pharmr.2026.100150_bib502","doi-asserted-by":"crossref","first-page":"29025","DOI":"10.1073\/pnas.2010984117","article-title":"Curtailing FGF19's mitogenicity by suppressing its receptor dimerization ability","volume":"117","author":"Niu","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmr.2026.100150_bib503","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1471-2407-12-56","article-title":"Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma","volume":"12","author":"Miura","year":"2012","journal-title":"BMC Cancer"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib504","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice","volume":"160","author":"Nicholes","year":"2002","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib505","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036713","article-title":"Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models","volume":"7","author":"French","year":"2012","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100150_bib506","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.1158\/0008-5472.CAN-07-2325","article-title":"Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling","volume":"68","author":"Pai","year":"2008","journal-title":"Cancer Res"},{"issue":"247","key":"10.1016\/j.pharmr.2026.100150_bib507","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009098","article-title":"A nontumorigenic variant of FGF19 treats cholestatic liver diseases","volume":"6","author":"Luo","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib508","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1158\/0008-5472.CAN-14-0208","article-title":"Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19","volume":"74","author":"Zhou","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib509","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-35496-z","article-title":"Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis","volume":"8","author":"Gadaleta","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib510","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s44321-023-00021-x","article-title":"FGF19 and its analog Aldafermin cooperate with MYC to induce aggressive hepatocarcinogenesis","volume":"16","author":"Ursic-Bedoya","year":"2024","journal-title":"EMBO Mol Med"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib511","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep4.1209","article-title":"NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial","volume":"2","author":"Mayo","year":"2018","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib512","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol"},{"issue":"10126","key":"10.1016\/j.pharmr.2026.100150_bib513","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib514","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jhep.2018.11.032","article-title":"Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis","volume":"70","author":"Rinella","year":"2019","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib515","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib516","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1053\/j.gastro.2020.08.004","article-title":"Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis","volume":"160","author":"Harrison","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib517","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2468-1253(22)00017-6","article-title":"Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2\/3): a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"7","author":"Harrison","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib518","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/HEP.0000000000000607","article-title":"A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis","volume":"79","author":"Rinella","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib519","article-title":"Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases","volume":"3","author":"Sanyal","year":"2021","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib520","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0378-1119(99)00309-1","article-title":"Characterization of the rat, mouse, and human genes of growth\/differentiation factor-15\/macrophage inhibiting cytokine-1 (GDF-15\/MIC-1)","volume":"237","author":"Bottner","year":"1999","journal-title":"Gene"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100150_bib521","doi-asserted-by":"crossref","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","article-title":"MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily","volume":"94","author":"Bootcov","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib522","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/nm1677","article-title":"Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1","volume":"13","author":"Johnen","year":"2007","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib523","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1158\/1078-0432.CCR-03-0165","article-title":"Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers","volume":"10","author":"Koopmann","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib524","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1073\/pnas.0530278100","article-title":"Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum","volume":"100","author":"Welsh","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib525","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib526","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2016.3","article-title":"Understanding cachexia as a cancer metabolism syndrome","volume":"5","author":"Porporato","year":"2016","journal-title":"Oncogenesis"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib527","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034868","article-title":"Macrophage inhibitory cytokine 1 (MIC-1\/GDF15) decreases food intake, body weight and improves glucose tolerance in mice on normal & obesogenic diets","volume":"7","author":"Macia","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib528","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055174","article-title":"TGF-b superfamily cytokine MIC-1\/GDF15 is a physiological appetite and body weight regulator","volume":"8","author":"Tsai","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib529","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.4393","article-title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL","volume":"23","author":"Emmerson","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib530","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm.4394","article-title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand","volume":"23","author":"Yang","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib531","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/nm.4392","article-title":"GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates","volume":"23","author":"Mullican","year":"2017","journal-title":"Nat Med"},{"issue":"7675","key":"10.1016\/j.pharmr.2026.100150_bib532","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature24042","article-title":"Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15","volume":"550","author":"Hsu","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pharmr.2026.100150_bib533","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55164.sa2","article-title":"The cytokine GDF15 signals through a population of brainstem cholecystokinin neurons to mediate anorectic signalling","author":"Worth","year":"2020","journal-title":"Elife"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib534","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1128\/MCB.20.10.3742-3751.2000","article-title":"Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury","volume":"20","author":"Hsiao","year":"2000","journal-title":"Mol Cell Biol"},{"issue":"7795","key":"10.1016\/j.pharmr.2026.100150_bib535","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","article-title":"GDF15 mediates the effects of metformin on body weight and energy balance","volume":"578","author":"Coll","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib536","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1093\/oxfordjournals.jbchem.a021798","article-title":"Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta","volume":"122","author":"Yokoyama-Kobayashi","year":"1997","journal-title":"J Biochem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib537","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cmet.2018.12.016","article-title":"GDF15 Provides an Endocrine Signal of Nutritional Stress in Mice and Humans","volume":"29","author":"Patel","year":"2019","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib538","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1515\/cclm-2022-0135","article-title":"Reference ranges for GDF-15, and risk factors associated with GDF-15, in a large general population cohort","volume":"60","author":"Welsh","year":"2022","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib539","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41574-021-00529-7","article-title":"GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease","volume":"17","author":"Wang","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib540","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcsm.12033","article-title":"Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients","volume":"6","author":"Lerner","year":"2015","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib541","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2010.05.032","article-title":"Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer","volume":"118","author":"Staff","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib542","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1111\/jcmm.12830","article-title":"Growth differentiation factor 15 is a promising diagnostic and prognostic biomarker in colorectal cancer","volume":"20","author":"Li","year":"2016","journal-title":"J Cell Mol Med"},{"issue":"7996","key":"10.1016\/j.pharmr.2026.100150_bib543","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/s41586-023-06921-9","article-title":"GDF15 linked to maternal risk of nausea and vomiting during pregnancy","volume":"625","author":"Fejzo","year":"2024","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib544","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/s41591-020-0945-x","article-title":"Antibody-mediated inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice","volume":"26","author":"Suriben","year":"2020","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib545","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111947","article-title":"GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia","volume":"42","author":"Kim-Muller","year":"2023","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib546","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41420-022-00972-z","article-title":"GDF-15 in tumor-derived exosomes promotes muscle atrophy via Bcl-2\/caspase-3 pathway","volume":"8","author":"Zhang","year":"2022","journal-title":"Cell Death Discov"},{"issue":"27","key":"10.1016\/j.pharmr.2026.100150_bib547","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106868118","article-title":"Activation of the hypothalamic-pituitary-adrenal axis by exogenous and endogenous GDF15","volume":"118","author":"Cimino","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib548","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1002\/jcsm.12939","article-title":"Hypothalamic-pituitary-adrenal axis activation and glucocorticoid-responsive gene expression in skeletal muscle and liver of Apc mice","volume":"13","author":"Martin","year":"2022","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib549","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.metabol.2011.06.012","article-title":"The effects of glucocorticoids on adipose tissue lipid metabolism","volume":"60","author":"Peckett","year":"2011","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib550","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41413-021-00178-6","article-title":"GDF15 promotes prostate cancer bone metastasis and colonization through osteoblastic CCL2 and RANKL activation","volume":"10","author":"Siddiqui","year":"2022","journal-title":"Bone Res"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib551","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/nm1629","article-title":"High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin","volume":"13","author":"Tanno","year":"2007","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib552","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12032-020-01439-w","article-title":"Iron overload is related to muscle wasting in patients with cachexia of gastric cancer: using quantitative proteome analysis","volume":"37","author":"Zhou","year":"2020","journal-title":"Med Oncol"},{"issue":"412","key":"10.1016\/j.pharmr.2026.100150_bib553","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan8732","article-title":"Long-acting MIC-1\/GDF15 molecules to treat obesity: Evidence from mice to monkeys","volume":"9","author":"Xiong","year":"2017","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib555","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cmet.2022.12.011","article-title":"Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist","volume":"35","author":"Benichou","year":"2023","journal-title":"Cell Metab"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib556","doi-asserted-by":"crossref","DOI":"10.2337\/db22-235-LB","article-title":"235-LB: YH34160, a novel long-acting GDF15 fusion protein, exerts potent and sustained body weight loss in rodent obesity models","volume":"71","author":"Lim","year":"2022","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib557","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/cts.13543","article-title":"A long-acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model","volume":"16","author":"Zheng","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.pharmr.2026.100150_bib558","first-page":"254","article-title":"Effect of CIN-109, a novel GDF-15 analog, on body weight and composition in subjects with obesity","volume":"32","author":"Bond","year":"2024","journal-title":"Obes (Silver Spring)"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib559","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1210\/clinem\/dgae550","article-title":"A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons","volume":"110","author":"Smith","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib560","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/jcsm.12077","article-title":"MAP3K11\/GDF15 axis is a critical driver of cancer cachexia","volume":"7","author":"Lerner","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib561","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102554","article-title":"Growth differentiation factor 15 neutralization does not impact anorexia or survival in lipopolysaccharide-induced inflammation","volume":"24","author":"Breen","year":"2021","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib562","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1158\/1078-0432.CCR-23-1631","article-title":"A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia","volume":"30","author":"Crawford","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib563","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309394","article-title":"Neutralizing antibody against GDF15 for treatment of cancer-associated cachexia","volume":"19","author":"Xiong","year":"2024","journal-title":"PLoS One"},{"issue":"13_Supplement","key":"10.1016\/j.pharmr.2026.100150_bib564","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-1828","article-title":"AZD8853: a novel antibody targeting GDF15 for immunotherapy refractory tumors","volume":"81","author":"Hurt","year":"2021","journal-title":"Cancer Research"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib565","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/jcsm.13219","article-title":"GDNF family receptor alpha-like antagonist antibody alleviates chemotherapy-induced cachexia in melanoma-bearing mice","volume":"14","author":"Lee","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.pharmr.2026.100150_bib566","doi-asserted-by":"crossref","first-page":"S610","DOI":"10.1016\/j.annonc.2021.08.1072","article-title":"550P Initial results of a phase Ia\/Ib study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients (pts) with advanced solid tumors","volume":"32","author":"Jain","year":"2021","journal-title":"Annals of Oncology"},{"issue":"22_Supplement","key":"10.1016\/j.pharmr.2026.100150_bib567","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.PANCA22-PR006","article-title":"Abstract PR006: initial results of a cohort of advanced pancreatic cancer patients in a phase 1b Study of NGM120, a first-in-class anti-GDNF Family Receptor Alpha Like (GFRAL) antibody","volume":"82","author":"Hendifar","year":"2022","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmr.2026.100150_bib568","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1888","article-title":"1402P Initial results of a cohort of advanced prostate cancer patients in a phase Ia study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody","volume":"33","author":"Medic","year":"2022","journal-title":"Annals of Oncology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib569","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107543","article-title":"GDF15 Induces an Aversive Visceral Malaise State that Drives Anorexia and Weight Loss","volume":"31","author":"Borner","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.pharmr.2026.100150_bib570","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.molmet.2019.01.003","article-title":"GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice","volume":"21","author":"Frikke-Schmidt","year":"2019","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib571","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13546","article-title":"Advances in the physiology of gastric emptying","volume":"31","author":"Goyal","year":"2019","journal-title":"Neurogastroenterology & Motility"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib572","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.cmet.2019.12.004","article-title":"GDF15 Induces Anorexia through Nausea and Emesis","volume":"31","author":"Borner","year":"2020","journal-title":"Cell Metab"},{"issue":"7968","key":"10.1016\/j.pharmr.2026.100150_bib573","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41586-023-06249-4","article-title":"GDF15 promotes weight loss by enhancing energy expenditure in muscle","volume":"619","author":"Wang","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib574","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ijo.2017.258","article-title":"Treatment with the TGF-b superfamily cytokine MIC-1\/GDF15 reduces the adiposity and corrects the metabolic dysfunction of mice with diet-induced obesity","volume":"42","author":"Tsai","year":"2018","journal-title":"Int J Obes (Lond)"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib575","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1083\/jcb.201607110","article-title":"Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis","volume":"216","author":"Chung","year":"2017","journal-title":"J Cell Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib576","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmet.2019.12.005","article-title":"Comprehensive Proteomics Analysis of Stressed Human Islets Identifies GDF15 as a Target for Type 1 Diabetes Intervention","volume":"31","author":"Nakayasu","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib577","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111503","article-title":"Growth differentiation factor-15 prevents glucotoxicity and connexin-36 downregulation in pancreatic beta-cells","volume":"541","author":"Asrih","year":"2022","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib578","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.2337\/db22-0019","article-title":"GDF15 Mediates the Effect of Skeletal Muscle Contraction on Glucose-Stimulated Insulin Secretion","volume":"72","author":"Zhang","year":"2023","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib579","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/oby.20638","article-title":"Lower NLRP3 inflammasome activity in NAG-1 transgenic mice is linked to a resistance to obesity and increased insulin sensitivity","volume":"22","author":"Wang","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib580","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17574-w","article-title":"GDF15 deficiency exacerbates chronic alcohol- and carbon tetrachloride-induced liver injury","volume":"7","author":"Chung","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib581","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jcmgh.2023.07.009","article-title":"GDF15 Ameliorates Liver Fibrosis by Metabolic Reprogramming of Macrophages to Acquire Anti-Inflammatory Properties","volume":"16","author":"Li","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib582","doi-asserted-by":"crossref","first-page":"6789","DOI":"10.1038\/s41598-018-25098-0","article-title":"Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.pharmr.2026.100150_bib583","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102070","article-title":"GDNF family receptor alpha-like (GFRAL) expression is restricted to the caudal brainstem","volume":"91","author":"Hes","year":"2025","journal-title":"Mol Metab"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib584","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.cell.2019.07.033","article-title":"GDF15 Is an Inflammation-Induced Central Mediator of Tissue Tolerance","volume":"178","author":"Luan","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib585","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-63880-5","article-title":"Growth\/differentiation factor 15 (GDF15) expression in the heart after myocardial infarction and cardioprotective effect of pre-ischemic rGDF15 administration","volume":"14","author":"Dogon","year":"2024","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib586","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.2354","article-title":"GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice","volume":"17","author":"Kempf","year":"2011","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100150_bib587","doi-asserted-by":"crossref","first-page":"10084","DOI":"10.1074\/jbc.M113.516278","article-title":"Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation","volume":"289","author":"Xu","year":"2014","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib588","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1161\/01.RES.0000202804.84885.d0","article-title":"GDF15\/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation","volume":"98","author":"Xu","year":"2006","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib589","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/jth.12100","article-title":"GDF-15 prevents platelet integrin activation and thrombus formation","volume":"11","author":"Rossaint","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib590","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1038\/s41467-023-39817-3","article-title":"Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment","volume":"14","author":"Haake","year":"2023","journal-title":"Nat Commun"},{"issue":"8048","key":"10.1016\/j.pharmr.2026.100150_bib591","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib592","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/2767-9764.CRC-24-0565","article-title":"First-in-human study to evaluate the safety and efficacy of anti-GDF15 antibody AZD8853 in patients with advanced\/metastatic solid tumors","volume":"5","author":"Carneiro","year":"2025","journal-title":"Cancer Research Communications"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib593","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf056","article-title":"The Glucagon Receptor Is Expressed in the Frontal Cortex and Impaired Signaling Associates With Cognitive Decline","volume":"9","author":"Kjeldsen","year":"2025","journal-title":"J Endocr Soc"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib594","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/0196-9781(95)00078-X","article-title":"Glucagon receptor mRNA distribution in rat tissues","volume":"16","author":"Hansen","year":"1995","journal-title":"Peptides"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib595","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib596","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-like peptide 1\/glucagon receptor dual agonism reverses obesity in mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"issue":"38","key":"10.1016\/j.pharmr.2026.100150_bib597","doi-asserted-by":"crossref","first-page":"15852","DOI":"10.1073\/pnas.1107394108","article-title":"PKA phosphorylation couples hepatic inositol-requiring enzyme 1alpha to glucagon signaling in glucose metabolism","volume":"108","author":"Mao","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib598","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1530\/JOE-16-0649","article-title":"Glucagon-induced extracellular cAMP regulates hepatic lipid metabolism","volume":"234","author":"Lv","year":"2017","journal-title":"J Endocrinol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib599","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib600","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.2337\/db25-0209","article-title":"Glucagon Receptor Deficiency Causes Early-Onset Hepatic Steatosis","volume":"74","author":"Cacciottolo","year":"2025","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib601","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/db12-0797","article-title":"Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia","volume":"62","author":"Tan","year":"2013","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib602","doi-asserted-by":"crossref","first-page":"E389","DOI":"10.1152\/ajpendo.00078.2022","article-title":"Glucagon receptor signaling at white adipose tissue does not regulate lipolysis","volume":"323","author":"Vasileva","year":"2022","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib603","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1096\/fj.201802048RR","article-title":"Loss of glucagon signaling alters white adipose tissue browning","volume":"33","author":"Townsend","year":"2019","journal-title":"FASEB J"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib604","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1210\/en.2014-1175","article-title":"Glucagon is essential for adaptive thermogenesis in brown adipose tissue","volume":"155","author":"Kinoshita","year":"2014","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib605","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.2337\/db14-0242","article-title":"Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake","volume":"63","author":"Cegla","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2026.100150_bib606","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib607","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cgh.2024.04.017","article-title":"Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis","volume":"22","author":"Shankar","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib608","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jhep.2024.06.003","article-title":"Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon\/glucagon-like peptide-1 receptor dual agonist, in cirrhosis","volume":"81","author":"Lawitz","year":"2024","journal-title":"J Hepatol"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib609","doi-asserted-by":"crossref","DOI":"10.2337\/db24-1857-LB","article-title":"1857-LB: Improvement of Liver Steatosis by Mazdutide in Chinese Participants with Overweight or Obesity\u2014An Exploratory Analysis of GLORY-1","volume":"73","author":"Ji","year":"2024","journal-title":"Diabetes"},{"issue":"209","key":"10.1016\/j.pharmr.2026.100150_bib610","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007218","article-title":"Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans","volume":"5","author":"Finan","year":"2013","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib611","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/db10-1332","article-title":"GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes","volume":"60","author":"Mentis","year":"2011","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib612","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1016\/j.cmet.2025.07.009","article-title":"Glucose-dependent insulinotropic polypeptide receptor signaling in oligodendrocytes increases the weight-loss action of GLP-1R agonism","volume":"37","author":"Hansford","year":"2025","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib613","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib614","article-title":"Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity","volume":"14","author":"Yuan","year":"2024","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib615","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The Sustained Effects of a Dual GIP\/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib616","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.107031","article-title":"Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis","volume":"199","author":"Ding","year":"2024","journal-title":"Pharmacol Res"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib617","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat Metab"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib619","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/CIRCULATIONAHA.124.072679","article-title":"Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity","volume":"151","author":"Zile","year":"2025","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib620","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1111\/bcp.14855","article-title":"Impact of glucagon-like peptide-1 receptor agonists on adiponectin concentrations: A meta-analysis of randomized controlled trials","volume":"87","author":"Simental-Mend\u00eda","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib621","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1177\/23969873241234238","article-title":"Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP\/GLP-1 receptor agonist tirzepatide for type 2 diabetes: A systematic review and meta-analysis","volume":"9","author":"Stefanou","year":"2024","journal-title":"Eur Stroke J"},{"key":"10.1016\/j.pharmr.2026.100150_bib622","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2023.09.007","article-title":"Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics","volume":"267","author":"Nicholls","year":"2024","journal-title":"Am Heart J"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100150_bib623","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib624","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70038","article-title":"Exploring Connections Between Weight-Loss Medications and Thyroid Cancer: A Look at the FDA Adverse Event Reporting System Database","volume":"8","author":"Abi Zeid Daou","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib625","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/dom.15382","article-title":"Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials","volume":"26","author":"Silverii","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib626","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"Veniant","year":"2024","journal-title":"Nat Metab"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib627","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMoa2504214","article-title":"Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial","volume":"393","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"49","key":"10.1016\/j.pharmr.2026.100150_bib628","doi-asserted-by":"crossref","first-page":"35581","DOI":"10.1074\/jbc.M113.512046","article-title":"A novel glucagon-like peptide-1 (GLP-1)\/glucagon hybrid peptide with triple-acting agonist activity at glucose-dependent insulinotropic polypeptide, GLP-1, and glucagon receptors and therapeutic potential in high fat-fed mice","volume":"288","author":"Gault","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib629","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib630","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2021.12.005","article-title":"Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1\/GIP\/GCG receptor triagonist","volume":"34","author":"Bossart","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib631","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2023.107176","article-title":"A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study","volume":"130","author":"Abdelmalek","year":"2023","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.pharmr.2026.100150_bib632","article-title":"\u4e50\u666e\u81ea\u613f\u62ab\u9732 GLP-1\/GCGR\/GIP-Fc \u878d\u5408\u86cb\u767d MWN101 \u5b8c\u6210\u2161\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7b2c\u4e00\u4f8b\u53d7\u8bd5\u8005\u7ed9\u836f","year":"2024","journal-title":"\u4e50\u666e (\u5317\u4eac) \u533b\u7597\u5668\u68b0\u80a1\u4efd\u6709\u9650\u516c\u53f8"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib633","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"issue":"1-2","key":"10.1016\/j.pharmr.2026.100150_bib635","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/17512433.2025.2450254","article-title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","volume":"18","author":"Tewari","year":"2025","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib636","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3233\/BMR-230065","article-title":"Prevalence and influencing factors of muscle mass loss in adults with diabetes and a high body fat percentage: a cross-sectional study","volume":"37","author":"Bi","year":"2024","journal-title":"J Back Musculoskelet Rehabil"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib637","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S2213-8587(24)00272-9","article-title":"Muscle matters: the effects of medically induced weight loss on skeletal muscle","volume":"12","author":"Prado","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2026.100150_bib638","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib639","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: a meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib640","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbrc.2012.12.105","article-title":"Myostatin acts as an autocrine\/paracrine negative regulator in myoblast differentiation from human induced pluripotent stem cells","volume":"431","author":"Gao","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib641","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2337\/db23-207-OR","article-title":"207-OR: myostatin inhibition synergizes with GLP-1R agonism to accelerate weight loss in male, obese nonhuman primates","volume":"72","author":"Mastaitis","year":"2023","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"10.1016\/j.pharmr.2026.100150_bib642","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2337\/db24-302-OR","article-title":"302-OR: the antimyostatin antibody SRK-439 promotes healthy body composition in combination with GLP-1RAs in a mouse model of obesity","volume":"73","author":"Fulham","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmr.2026.100150_bib643","series-title":"Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass","year":"2025"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib645","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/dom.14663","article-title":"Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms","volume":"24","author":"Ghidewon","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib646","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2468-1253(22)00338-7","article-title":"Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease","volume":"8","author":"Targher","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.pharmr.2026.100150_bib647","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101718","article-title":"Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets","volume":"72","author":"Le","year":"2023","journal-title":"Mol Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib648","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ebiom.2019.02.037","article-title":"Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output","volume":"41","author":"Liu","year":"2019","journal-title":"EBioMedicine"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib649","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1210\/en.2009-0915","article-title":"GLP-1(7-36)-amide and Exendin-4 stimulate the HPA axis in rodents and humans","volume":"151","author":"Gil-Lozano","year":"2010","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib650","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1210\/en.2013-1718","article-title":"Corticotropin-releasing hormone and the sympathoadrenal system are major mediators in the effects of peripherally administered exendin-4 on the hypothalamic-pituitary-adrenal axis of male rats","volume":"155","author":"Gil-Lozano","year":"2014","journal-title":"Endocrinology"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100150_bib651","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s00125-015-3727-0","article-title":"Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice","volume":"58","author":"Kooijman","year":"2015","journal-title":"Diabetologia"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib652","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.cmet.2016.08.003","article-title":"iNKT cells induce FGF21 for thermogenesis and are required for maximal weight loss in GLP1 therapy","volume":"24","author":"Lynch","year":"2016","journal-title":"Cell Metab"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib653","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1007\/s00125-011-2317-z","article-title":"Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial","volume":"54","author":"Samson","year":"2011","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib654","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15620","article-title":"Short-term semaglutide treatment improves FGF21 responsiveness in primary hepatocytes isolated from high fat diet challenged mice","volume":"11","author":"Feng","year":"2023","journal-title":"Physiol Rep"},{"issue":"35","key":"10.1016\/j.pharmr.2026.100150_bib655","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaz9890","article-title":"Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia","volume":"6","author":"Gilroy","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.pharmr.2026.100150_bib656","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103202","article-title":"A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis","volume":"63","author":"Pan","year":"2021","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib657","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3803\/EnM.2020.781","article-title":"Effects of glucagon-like peptide-1 analogue and fibroblast growth factor 21 combination on the atherosclerosis-related process in a type 2 diabetes mouse model","volume":"36","author":"Kim","year":"2021","journal-title":"Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib658","doi-asserted-by":"crossref","DOI":"10.5812\/ijpr-131015","article-title":"Design of a dual agonist of exendin-4 and FGF21 as a potential treatment for type 2 diabetes mellitus and obesity","volume":"22","author":"Zhang","year":"2023","journal-title":"Iran J Pharm Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib659","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13287-021-02205-z","article-title":"Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice","volume":"12","author":"Xue","year":"2021","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib660","first-page":"144","article-title":"Incretin-FGF21 fusion molecule maximizes metabolic effects in mice","volume":"56","author":"Kong","year":"2024","journal-title":"Acta Biochim Biophys Sin"},{"key":"10.1016\/j.pharmr.2026.100150_bib661","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(25)01598-3","article-title":"FRI-365 DR10624, a novel FGF21R, GCGR, and GLP-1R tri-agonist, demonstrated extraordinary efficacy in B6-Alms1-del mice, a spontaneous MASH model of mice with obesity, hyperglycemia, and dyslipidemia phenotype","volume":"82","author":"Fang","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmr.2026.100150_bib662","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/S0168-8278(25)00422-2","volume":"82","author":"Fang","year":"2025","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib663","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","article-title":"Fibroblast growth factor 21 mediates specific glucagon actions","volume":"62","author":"Habegger","year":"2013","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib664","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2337\/db17-1502","article-title":"Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid X receptor and fibroblast growth factor 21","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100150_bib665","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1007\/s00018-019-03255-6","article-title":"Dual CCR5\/CCR2 targeting: opportunities for the cure of complex disorders","volume":"76","author":"Fantuzzi","year":"2019","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib666","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.pharmr.2026.100150_bib667","doi-asserted-by":"crossref","first-page":"d793","DOI":"10.2741\/gressner","article-title":"Roles of TGF-beta in hepatic fibrosis","volume":"7","author":"Gressner","year":"2002","journal-title":"Front Biosci"},{"key":"10.1016\/j.pharmr.2026.100150_bib668","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.627927","article-title":"Activated hepatic stellate cells induce infiltration and formation of CD163(+) macrophages via CCL2\/CCR2 pathway","volume":"8","author":"Xi","year":"2021","journal-title":"Front Med"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100150_bib669","first-page":"1858","article-title":"CCR1 and CCR5 promote hepatic fibrosis in mice","volume":"119","author":"Seki","year":"2009","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib670","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hep.22952","article-title":"CCR2 promotes hepatic fibrosis in mice","volume":"50","author":"Seki","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib671","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/hep.26783","article-title":"Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C(+) macrophage infiltration in mice","volume":"59","author":"Baeck","year":"2014","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib672","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011049","article-title":"Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis","volume":"5","author":"Zimmermann","year":"2010","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib673","doi-asserted-by":"crossref","first-page":"6696","DOI":"10.3390\/ijms23126696","article-title":"Combined therapy with a CCR2\/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis","volume":"23","author":"Puengel","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib674","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1111\/dom.13206","article-title":"Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 study","volume":"20","author":"Jabbour","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100150_bib675","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.2337\/dc18-0680","volume":"41","author":"Jabbour","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib676","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib677","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.pharmr.2026.100150_bib678","article-title":"The efficacy and safety of the combination therapy with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib679","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103890","article-title":"A network-based computational and experimental framework for repurposing compounds toward the treatment of non-alcoholic fatty liver disease","volume":"25","author":"Zareifi","year":"2022","journal-title":"iScience"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib680","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.14139","article-title":"Use of artificial intelligence in drug development","volume":"7","author":"Druedahl","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100150_bib681","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.tem.2024.04.019","article-title":"Digital twins and artificial intelligence in metabolic disease research","volume":"35","author":"Mosquera-Lopez","year":"2024","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.pharmr.2026.100150_bib682","article-title":"Liver-on-chips for drug discovery and development","volume":"27","author":"Mehta","year":"2024","journal-title":"Mater Today Bio"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib683","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1124\/pharmrev.120.000238","article-title":"Organotypic and microphysiological human tissue models for drug discovery and development-current state-of-the-art and future perspectives","volume":"74","author":"Youhanna","year":"2022","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib684","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s43856-022-00209-1","article-title":"Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology","volume":"2","author":"Ewart","year":"2022","journal-title":"Commun Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100150_bib686","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-022-00466-9","article-title":"Human organs-on-chips for disease modelling, drug development and personalized medicine","volume":"23","author":"Ingber","year":"2022","journal-title":"Nat Rev Genet"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100150_bib687","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1136\/gutjnl-2021-326560","article-title":"Organoids in gastrointestinal diseases: from experimental models to clinical translation","volume":"71","author":"G\u00fcnther","year":"2022","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib688","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41573-020-0079-3","article-title":"Organs-on-chips: into the next decade","volume":"20","author":"Low","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100150_bib689","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1038\/s41467-024-52258-w","article-title":"Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system","volume":"15","author":"Qi","year":"2024","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100150_bib690","article-title":"Microengineered multi-organoid system from hipscs to recapitulate human liver-islet axis in normal and type 2 diabetes","volume":"9","author":"Tao","year":"2022","journal-title":"Adv Sci"},{"issue":"34","key":"10.1016\/j.pharmr.2026.100150_bib691","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202203368","article-title":"Bioengineered pancreas-liver crosstalk in a microfluidic coculture chip identifies human metabolic response signatures in prediabetic hyperglycemia","volume":"9","author":"Zandi Shafagh","year":"2022","journal-title":"Adv Sci"},{"key":"10.1016\/j.pharmr.2026.100150_bib692","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104080","article-title":"Patient-derived microphysiological model identifies the therapeutic potential of metformin for thoracic aortic aneurysm","volume":"81","author":"Ma","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib693","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/hep.31106","article-title":"Liver-on-a-chip models of fatty liver disease","volume":"71","author":"Hassan","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100150_bib694","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cmet.2019.05.007","article-title":"Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids","volume":"30","author":"Ouchi","year":"2019","journal-title":"Cell Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100150_bib695","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1053\/j.gastro.2020.06.010","article-title":"Human pluripotent stem cell-derived organoids as models of liver disease","volume":"159","author":"Ramli","year":"2020","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100150_bib696","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.2337\/db18-0155","article-title":"Glucagon-like peptide 1 increases \u03b2-cell regeneration by promoting \u03b1- to \u03b2-cell transdifferentiation","volume":"67","author":"Lee","year":"2018","journal-title":"Diabetes"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100150_bib697","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1042\/CS20190093","article-title":"Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic \u03b2-cell dysfunction via regulation of AMPK signaling and lipid metabolism","volume":"133","author":"Xie","year":"2019","journal-title":"Clin Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100150_bib698","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00125-022-05822-2","article-title":"Pancreatic alpha cell glucagon-liver FGF21 axis regulates beta cell regeneration in a mouse model of type 2 diabetes","volume":"66","author":"Cui","year":"2023","journal-title":"Diabetologia"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:28:22Z","timestamp":1790245702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":686,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0031699726000384"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100150","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide hormone-based combinational pharmacotherapies for chronic metabolic diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100150"}}